document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report table content item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale pharmaceutical product global basis year execute strategy transform generation biopharmaceutical company transformation encompass area business operation strategy divest nonpharmaceutical business implement acquisition licensing strategy know stringofpearl execute productivity transformation initiative pti respect divestiture sell medical imaging business january sell convatec business august divest mead johnson nutrition company mead johnson december period complete numerous acquisition licensing transaction include acquisition adnexus therapeutics inc october kosan biosciences inc june medarex incmedarex september complement divestiture acquisition execute productivity transformation initiative enhance efficiency effectiveness competitiveness continue improve cost base pti reduce general administrative operation simplify standardize outsource certain process service rationalize mature brand portfolio consolidated global manufacturing network eliminate complexity enhance profitability simplify geographic footprint implement efficient gotomarket model meeting pti target implement culture continuous improvement report financial operating information segmentbiopharmaceutical additional information business segment item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product united states puerto rico foreign country net sale account total net sale respectively net sale europe middle east africa account total net sale net sale japan account total net sale net sale canada account total net sale product pharmaceutical product include chemicallysynthesize drug small molecule increase portion biological product biologic large molecule small molecule drug typically administer orally form pill drug delivery mechanism biologic typically administer patient injection revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infection oncology neuroscience immunoscience metabolic pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity business focus innovative biopharmaceutical product rely patent right form regulatory protection maintain market exclusivity product european union country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition business generic competition chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan canada sell pharmaceutical product country datum provide country bycountry basis individual country sale significant outside japan canada instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date table content datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate follow schedule present net sale key product estimate basic exclusivity loss japanese canadian market net sale product past currently estimate year basic exclusivity loss key product japan canada dollar million cardiovascular plavix avaproavalide virology reyataz sustiva franchise total revenue baraclude oncology erbitux sprycel ixempra neuroscience abilify immunoscience orencia metabolics onglyza note currently estimate early year basic exclusivity loss include statutory extension exclusivity earn grant instance able obtain additional month exclusivity product base pediatric extension example certain instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position product product exclusivity predict assure note product file biologic license application bla year exclusivity list year patent expiration currently regulatory pathway approval followon biologic product describe detail intellectual property product exclusivity indicate brand name product register trademark own subsidiary specific trademark ownership information find currently market product country region indicate reference include member states members european union year end december basic patent application file current member state list product instance date basic exclusivity loss different member states instances early late date basic exclusivity loss list country basic patent obtain datum protection available data exclusivity expire july major market europe product national patent expiring specifically claim bisulfate form clopidogrel generic alternate salt form clopidogrel bisulfate market compete plavix data exclusivity expire exclusivity period relate sustiva brand include exclusivity relate combination therapy right commercialize cetuximab terminate possible accurately assess length exclusivity erbitux biologic currently regulatory approval path generic biologic expect change future pende application patent application file estonia latvia lithuania malta slovakia slovenia ixabepilone approve market approve market switzerland composition matter patent expect expire right commercialize aripiprazole terminate april rights commercialize aripiprazole terminate patent protection romania denmark expire biologic product approve bla currently regulatory approval path generic biologic expect change future data exclusivity expire datum exclusivity japan expire exclusivity period base regulatory datum protection table content summary indication intellectual property position product partner thirdparty manufacturing arrangement product applicable japan canada cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome plavix label update new warning use prilosec omeprazole certain drug interfere plavix reduce effectiveness label update include warning variability response attribute cyp genetic polymorphism currently discussion food drug administration fda possible additional change plavix label clopidogrel bisulfate codevelope jointly market sanofiaventis sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration composition matter patent currently expire november include possible month pediatric extension subject patent litigation apotex generic company significant jurisdiction information litigation matter item financial statementsnote legal proceeding contingency regulatory datum exclusivity protection expire july major market europe plavix benefit national patent expire specifically claim bisulfate form clopidogrel remainder member country composition matter patent cover clopidogrel bisulfate plavix subject competition market generic clopidogrel bisulfate market composition matter patent alternative salt form clopidogrel sanofi hold patent obtain bulk requirement clopidogrel bisulfate sanofi thirdparty company sanofi finish product facility avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi information alliance sanofi strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent expire include pediatric extension country data exclusivity expire august avapro october avalide irbesartan manufacture company sanofi manufacture bulk requirement irbesartan finish avaproavalide facility avalide purchase bulk requirement hydrochlorothiazide thirdparty virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launch july develop atazanavir worldwide license novartis pharmaceutical corporation novartis royalty pay base percentage net sale entitle promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories amend royalty pay base percentage net sale market exclusivity reyataz expect expire major member country japan data exclusivity expire patent subject patent litigation information litigation matter item financial statementsnote legal proceeding contingency manufacture bulk requirement atazanavir finish product facility table content sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine sustiva gilead sciences inc gilead truvada emtricitabine tenofovir disoproxil fumarate atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider information arrangement gilead strategic alliance collaboration item financial statementsnote alliance collaboration right market efavirenz canada united kingdom france germany ireland italy spain license merck inc royalty base percentage net sale composition matter patent efavirenz expire method use patent treatment hiv infection expire possible month pediatric extension market exclusivity sustiva expect expire country company market efavirenz japan certain atripla patent subject patent litigation time patent cover efavirenz composition matter method use challenge information litigation matter item financial statementsnote legal proceeding contingency obtain bulk requirement efavirenz party produce finished good facility provide bulk efavirenz gilead responsible produce finished atripla product baraclude entecavir potent selective inhibitor hepatitis virus approve fda march treatment chronic hepatitis infection baraclude discover develop internally approve market country outside include china japan composition matter patent expire composition matter patent expire japan uncertainty chinas exclusivity law uncertainty possible company china receive marketing authorization china health authority time produce market generic form entecavir china manufacture bulk requirement entecavir finish product facility oncology erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan fda approve erbitux use treatment squamous cell carcinoma head neck specifically erbitux approve use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail october fda accept file supplemental biologic license application sbla firstline squamous cell carcinoma head neck grant priority review status fda request interim datum additional study complete review application continue work fda provide request information table content erbitux market north america agreement imclone system incorporate imclone predecessor company imclone llc whollyowne subsidiary eli lilly company lilly share copromotion rights erbitux merck kgaa japan codevelopment cocommercialization agreement sign october imclone merck kgaa merck japan erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer description alliance imclone strategic alliance collaboration item financial statementsnote alliance collaboration patent specifically claim composition matter cetuximab active molecule erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire inventorship use patent challenge researcher yeda research development company ltd yeda pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent settlement agreement change distribution fee pay imclone erbitux sale yeda right license use patent yeda license patent party result product competition erbitux occur unable assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux obtain finish good requirement cetuximab use north america lilly lilly manufacture bulk requirement cetuximab facility finish perform thirdparty lilly description supply agreement lilly manufacture quality assurance sprycel dasatinib multitargete tyrosine kinase inhibitor approve treatment adult phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy patent term extension grant extend term basic composition matter patent cover dasatinib june country patent pende grant expire april exclude term extension new chemical entity regulatory exclusivity protection expire orphan drug exclusivity expire protect product generic application currently approve orphan indication dasatinib discover develop internally april enter oncology collaboration agreement otsuka pharmaceutical ltd otsuka cover sprycel ixempra ixabepilone information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration manufacture bulk requirement dasatinib finish product facility ixempra ixabepilone microtubule inhibitor belong class antineoplastic agent epothilone analogs fda approve ixabepilone combination capecitabine treatment patient metastatic locallyadvance breast cancer resistant treatment anthracycline taxane cancer taxane resistant anthracycline therapy contraindicate monotherapy treatment metastatic locallyadvance breast cancer patient tumor resistant refractory anthracycline taxane capecitabine withdraw marketing authorization application march basic composition matter patent protect ixabepilone expire patent term extension request grant extend patent term september new chemical entity regulatory exclusivity protection expire table content ixabepilone develop subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relate epothilone technology pay royalty base percentage net sale april enter oncology collaboration agreement otsuka cover sprycel ixempra information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration manufacture bulk requirement ixabepilone facility include manufacture active ingredient drug product comprise pharmaceutical kit finish baxter oncology gmbh neuroscience abilify aripiprazole atypical antipsychotic agent patient schizophrenia bipolar mania disorder major depressive disorder global commercialization agreement otsuka japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt information arrangement otsuka strategic alliance collaboration item financial statementsnote alliance collaboration basic composition matter patent abilify expire april include grant patent term extension month pediatric extension basic composition matter patent protect aripiprazole subject patent litigation otsuka sole right enforce patent information litigation matter item financial statement note legal proceeding contingency composition matter patent force germany france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplementary protection certificate country romania denmark datum exclusivity expire obtain bulk requirement aripiprazole otsuka company otsuka finish product facility immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept approve fda december commercially available february orencia discover develop internally series patent cover abatacept method use patent term extension grant composition matter patent extend term patent majority country patent covering abatacept expire majority country apply supplementary protection certificate extend term patent grant datum exclusivity expire obtain bulk abatacept thirdparty manufacturing facility finish product facility table content metabolic onglyza saxagliptin dipeptidyl peptidase inhibitor oral compound indicate treatment type diabete adjunct diet exercise onglyza discover internally worldwide japan codevelopment cocommercialization agreement astrazeneca plc astrazeneca saxagliptin information arrangement astrazeneca otsuka japan strategic alliance collaboration item financial statementsnote alliance collaboration patent cover saxagliptin composition matter expire manufacture bulk requirement saxagliptin facility include manufacture active ingredient company thirdparty finish product facility emerge market refine focus emerge market represent significant opportunity growth market characterize strong economic development rise gross domestic product grow middle class increase wealth middle class demand quality healthcare emerge market provide growth opportunity pharmaceutical industry middle decade strategy capitalize growth opportunity innovationfocuse approach approach develop commercialize select innovative product key highgrowth market tailor approach market individually identify emerge market focus brazil russia india china turkey emerge public health interest country good align strategy current portfolio pipeline country identify improve intellectual property protection order capitalize growth opportunity emerge market balance relate risk develop innovative pricing access strategy product accessible patient provide reasonable return investment risk include intellectual property protection currency volatility reimbursement issue government stability scale issue market address research development invest heavily research development believe critical longterm competitiveness major facility princeton hopewell new brunswick new jersey wallingford connecticut milpita california pharmaceutical research development carry facility belgium canada india management continue emphasize leadership innovation productivity quality strategy success research development activity spend billion billion billion research development activity research development spending include payment thirdparty collaboration contract end employ approximately people activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel concentrate biopharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia cardiovascular primarily atherosclerosisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient drug discovery program include alliance collaborative agreement agreement bring new product pipeline help remain cut edge technology search novel medicine drug development engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product drug development time consume expensive risky development human health product industry practice government regulation foreign country provide determination effectiveness safety new molecular entity preclinical test control clinical evaluation new drug marketed table content record datum preclinical clinical experience include product application fda european medicines agency ema respectively require regulatory approval average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine process discovery regulatory approval typically take year long drug candidate fail stage process latestage product candidate fail receive regulatory approval list latestage investigational compound phase iii clinical trial potential indication investigational compound ultimately market product depend result clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance seek regulatory approval compound approval sought obtain assurance compound approve commercially successful stage development determine intellectual property issue patent protection available investigational compound patent coverage highlight include patent term extension grant include potential patent term extension apixaban apixaban oral factor inhibitor phase iii clinical trial prevention venous thromboembolic disorder treatment acute coronary syndrome stroke prevention atrial fibrillation april enter worldwide agreement pfizer inc pfizer codevelopment cocommercialization apixaban patent cover apixaban composition matter expire belatacept belatacept biological product fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection september fda accept file review submission biologic license application belatacept prescription drug user fee act pdufa goal fda action january fda announce cardiovascular renal drug advisory committee plan meet march provide advice application patent cover belatacept composition matter expire brivanib brivanib oral small molecule dual kinase inhibitor blocks vegf receptor fgf receptor currently phase iii trial anticancer treatment potential use hepatocellular carcinoma colorectal cancer patent cover brivanib composition matter expire dapagliflozin dapagliflozin oral compound potential treatment diabete currently phase iii clinical trial enter agreement astrazeneca codevelopment cocommercialization dapagliflozin worldwide patent cover dapagliflozin composition matter currently expire october ipilimumab ipilimumab biologic product monoclonal antibody currently phase iii development treatment metastatic melanoma study lung cancer adjuvant melanoma hormonerefractory prostate cancer novel class agent intend potentiate element immunologic response compound discover medarex subsidiary patent cover ipilimumab composition matter currently expire necitumumab necitumumab fully human monoclonal antibody investigate anticancer treatment discover imclone alliance company lilly study outside lung cancer colorectal cancer phase iii trial non small cell lung cancer lilly own patent cover composition matter expire oral anticancer compound discover licensed exelixis phase iii clinical trial medullary thyroid cancer target enzyme meet encourage tumor cell survival movement vegf help tumor develop new blood vessel ret involve cell growth migration find thyroid cancer exelixis own patent cover composition matter expire exclusively license recently terminate development program tanespimycin phase iii trial potential treatment multiple myeloma table content strategic alliance collaboration enter strategic alliance collaboration party right develop manufacture market andor sell pharmaceutical product own party party right develop manufacture market andor sell pharmaceutical product own alliance collaboration form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense compound lead revenuegenerate product profitability alliance product generally low substantially profitability product partner profit alliance product share alliance partner assurance new alliance form actively pursue arrangement view alliance important complement discovery development activity strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occur cure number alliance agreement permit collaborator terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse collaboration agreement sign strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general retain right product bring alliance party party intellectual property alliance terminate loss right product market sell pursuant strategic alliance arrangement material result operation cash flow case plavix abilify material financial condition liquidity customary pharmaceutical industry term strategic alliance arrangement generally coextensive exclusivity period vary countrybycountry basis significant current alliance arrangement currently market product investigational compound describe current marketed productsinlicensed sanofi agreement sanofi codevelopment cocommercialization avaproavalide plavix avaproavalide copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside tradename karveakarvezide plavix copromote certain country outside tradename plavix comarkete certain country outside tradename iscover worldwide alliance operate framework geographic territory cover certain european asian country refer territory cover puerto rico canada australia certain latin american country refer territory territory manage separate set agreement plavix puerto rico products australia mexico brazil colombia argentina separate set agreement avaproavalide puerto rico territory territory partnership exist supply finish product country territory manage contract certain central expense market research development royalty country territory structured local affiliate sanofis local affiliate comarket separate brand affiliate operate independently compete sell product different trademark copromote single brand product trademark territory comarketing country include germany spain italy irbesartan greece china clopidogrel bisulfate sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden taiwan korea singapore hong kong aprovelcoaprovel certain french export country sanofi act operating partner territory own financial control interest territory ownership interest territory account investment partnership entity territory equity method recognize table content share result equity net income affiliate share net income partnership entity tax million million million territory company sanofi copromote plavix avaproavalide canada puerto rico territory countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country act operating partner territory majority control interest territory consolidate partnership result territory recognize sanofis share result net earning attributable noncontrolle interest net taxis million million million recognize net sale territory territory comarkete country billion billion billion territory partnership govern series committee enumerate function power responsibilitie territory senior committee final decisionmake authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia expiration patent exclusivity right relate product applicable territory alliance arrangement terminate sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory increase combine cost good royalty exceed specify percentage net selling price product good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event lose right product applicable relevant country territory case bankruptcy insolvency material breach default party discussion strategic alliance sanofi item financial statementsnote alliance collaboration otsuka maintain worldwide commercialization agreement otsuka codevelop copromote abilify abilify agreement japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt collaboration agreement otsuka relate certain oncology product oncology agreement fully describe current market productsinternally discover term abilify agreement amend purchase product otsuka perform finish manufacturing sale otsuka party customer abilify agreement expire april june countries country exclusive right sell abilify agreement expire later april loss exclusivity country germany france spain product invoice thirdparty customer behalf otsuka recognize alliance revenue contractual share thirdparty net sale germany france spain contractual share net sale recognize expense relate product contractual share net sale term agreement otsuka extend portion abilify agreement describe fully recognize expense relate product otsuka responsible commercialization expense relate product italy presently exclusive distributor product recognize net sale relate cost product sell expense exclusive right sell abilify country europe americas number countries asia country recognize net sale relate cost product sell table content april company otsuka extend portion abilify agreement expect loss product exclusivity april term extension pay otsuka million begin january share net sale recognize abilify change follow share net sale period otsuka responsible expense relate commercialization abilify begin january expect loss exclusivity april receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify portion abilify agreement oncology agreement describe include changeofcontrol provision acquire acquire company compete product abilify new company assume abilify agreement amend oncology agreement currently exist acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire right abilify agreement amend price accord predetermine schedule agreement provide event generic competitor abilify january option terminate abilify april amendment agreement previously amend remain force exercise option receive payment otsuka accord predetermine schedule oncology agreement terminate time oncology agreement continue truncated period accord predetermine schedule early termination abilify agreement immediate notice case voluntary bankruptcy minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event challenge otsuka patent right marketbymarket basis event market product direct competition abilify termination expiration abilify agreement retain right abilify recognize net sale abilify billion billion billion addition million extension payment total upfront licensing milestone payment otsuka abilify agreement million discussion oncology agreement otsuka current market productsinternally discover discussion strategic alliance otsuka item financial statementsnote alliance collaboration lilly commercialization agreement lilly lillys subsidiary imclone cover erbitux rights canada japan extent product commercialize country agreement cover north america lilly receive distribution fee base flat rate net sale north america party share profit evenly japan party share royalty payable party pursuant formula set forth commercialization agreement purchase commercial requirement bulk erbitux lilly price equal lillys manufacturing cost plus agreement expire erbitux north america september early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice exist table content significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance retain right erbitux share codevelopment copromotion right erbitux merck kgaa japan agreement sign october expire lilly merck kgaa merck japan lilly ability terminate agreement determine commercially unreasonable continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer recognize net sale erbitux million million million respectively discussion strategic alliance lilly item financial statementsnote alliance collaboration gilead joint venture gilead develop commercialize atripla canada europe company gilead share responsibility commercialize atripla canada certain european country provide fund fieldbased sale representative support promotional effort atripla gilead recognize atripla revenue canada countries europe revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand recognize efavirenz revenue million million million respectively relate atripla net sale joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version party component product appear market party right terminate joint venture acquire right combination product canada year terminate party continue receive percentage net sale base contribution bulk component atripla retain right product discussion strategic alliance gilead item financial statementsnote alliance collaboration current market productsinternally discover astrazeneca january enter worldwide japan codevelopment cocommercialization agreement astrazeneca onglyza saxagliptin agreement company astrazeneca party codevelopment cocommercialization agreement dapagliflozin describe investigational compound developmentinternally discover manufacture onglyza certain limited exception recognize net sale key market receive million upfront licensing milestone payment astrazeneca meet certain development regulatory milestone onglyza receive additional million remain development regulatory milestone saxagliptin agreement meet additional million salesbased milestone meet majority cost initial development plan pay astrazeneca additional development cost generally share equally expense onglyza development cost net astrazenecas share research development company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration table content otsuka simultaneously extension abilify agreement april company otsuka enter oncology agreement sprycel ixempra include japan market oncology territory begin collaboration fee pay otsuka annually follow percentage aggregate net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product oncology territory commercial operational expense relate product oncology territory excess million start otsuka right copromote sprycel japan market oncology agreement expire respect sprycel ixempra include changeofcontrol provision acquire abilify agreement describe discussion abilfy agreement otsuka current market productsinlicense discussion strategic alliance otsuka item financial statementsnote alliance collaboration investigational compound developmentinlicense exelixis december company exelixis inc exelixis enter global codevelopment cocommercialization arrangement license utility ras raf mutant tumor development exelixis term arrangement pay exelixis million execution agreement additional million exelixis fund million development exelixis elect continue share development cost elect copromote exelixis fund future global development cost exclude japan share profit loss equally fail election exelixis receive milestone royalty net sale royalty percentage rate tiere base net sale fund development cost japan addition royalty nonus net sale pay million development regulatory milestone meet compound additional million salesbased milestone meet compound addition company exelixis history collaboration identify develop promote oncology target january company exelixis enter oncology collaboration license agreement exelixis purse development small molecule ind codevelopment copromotion term agreement pay exelixis million upfront licensing milestone payment date exelixis elect fund development cost copromote party equally share development cost profit exelixis optsout codevelopment copromotion agreement development commercial right successful pay exelixis development regulatory milestone million additional million salesbased milestone royaltie royalty percentage rate tiere base net sale july hold equity interest exelixis december represent outstanding share zymogenetics january company zymogenetics inc zymogenetic enter global codevelopment arrangement peg interferon lambda novel type interferon treatment hepatitis term arrangement pay zymogenetic million upfront licensing milestone payment zymogenetics fund million global development peginterferon lambda zymogenetics fund development cost europe fund development cost europe development cost rest world zymogenetic elect continue share development commercialization cost zymogenetic share profit loss option copromote fail election fund development cost zymogenetic receive royalty net sale royalty percentage rate tiere base net sale pay zymogenetic royalty nonus net sale addition pay million hepatitis development regulatory milestone meet million development regulatory milestone potential indication meet additional million salesbased milestone meet table content discussion strategic alliance zymogenetic item financial statementsnote alliance collaboration lilly january company lilly restructure erbitux commercialization agreement provide codevelopment cocommercialization necitumumab imcf fully human antibody currently phase iii development nonsmall cell lung cancer restructure company share cost develop share profit loss commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market fund development cost study fund global study pay million lilly milestone payment approval grant canada recognize sale receive profit necitumumab lilly provide selling effort japan company lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate lilly manufacture bulk requirement finish product alder november company alder biopharmaceuticals inc alder enter global agreement development commercialization ald novel biologic complete phase iia development treatment rheumatoid arthritis term collaboration agreement alder grant worldwide exclusive right develop commercialize ald potential indication cancer alder retain right grant option codevelop exclusive right cocommercialize outside united states pay alder million upfront licensing payment expense research development addition pay million developmentbase regulatorybase milestone payment potential salesbased milestone certain circumstance exceed million royalty net sale royalty percentage rate tiere base net sale choose option pursue cancer indication pay additional million developmentbased regulatorybase milestone payment aforementione salesbased milestone royalty net sale royalty percentage rate tiere base net sale investigational compound developmentinternally discover astrazeneca mention worldwide codevelopment cocommercialization agreement astrazeneca dapagliflozin sglt agreement dapagliflozin study potential treatment diabete discover sglt agreement receive million upfront licensing payment astrazeneca receive million development regulatory milestone meet dapagliflozin additional million salesbased milestone meet majority cost initial plan pay astrazeneca additional development cost generally share equally japan astrazeneca bear substantially development cost prior approval indication expense dapagliflozin development cost net alliance partner share research development sglt agreement like saxagliptin agreement company jointly develop clinical marketing strategy share commercialization expense profit loss dapagliflozin equally global basis manufacture dapagliflozin certain limited exception recognize net sale key market respect japan astrazeneca operational cost responsibility development regulatory activity behalf collaboration company jointly market product japan share commercialization expense activity split profit loss equally like rest world manufacture dapagliflozin recognize net sale japan like rest world dapagliflozin currently study phase clinical trial japan discussion strategic alliance astrazeneca item financial statementsnote alliance collaboration pfizer company pfizer party worldwide codevelopment cocommercialization agreement apixaban anticoagulant discover study prevention treatment broad range venous arterial thrombotic condition pfizer fund development cost january fund receive million upfront licensing milestone payment pfizer date receive additional million pfizer development regulatory milestone meet company jointly develop clinical marketing strategy apixaban share commercialization expense profit loss equally global basis discussion strategic alliance pfizer item financial statementsnote alliance collaboration otsuka january grant otsuka exclusive right japan develop commercialize onglyza entitle receive milestone payment base certain regulatory event salesbase payment follow regulatory approval table content onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan royalty licensing arrangement addition strategic alliance describe inlicense outlicense arrangement respect inlicense agreement novartis reyataz hzi ixempra base current expectation respect expiration market exclusivity significant market license arrangement novartis reyataz expect expire japan arrangements hzi ixempra expect expire anniversary commercial sale japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur japan canada product result acquisition medarex inc medarex august certain compound outlicense party development commercialization expect receive milestone payment compound regulatory process royalty base product sale product commercialize intellectual property product exclusivity license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan canada certain market regulatory intellectual property right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive extend market exclusivity period product patent term japan canada provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy datum protection certain market patent protection form market exclusivity expire datum protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator specific aspect law govern market exclusivity datum protection pharmaceuticals vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term innovator depend number factor extend expiration date patent maximum term year provide extension cause patent effect year date drug approval table content company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical company file new drug application nda medicine biological product bla file type application file affect regulatory exclusivity right competitor seek launch generic substitute chemical innovative drug file abbreviate nda anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda currently law abbreviate path regulatory approval generic version biological product bill draft legislation change introduce congress fda take step allow generic version certain biologic innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition benefit patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical entitle year regulatory data protection competitor file fda approval generic substitutes innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation new indication basis new clinical trial receive year datum protection formulation indication increase likelihood generic challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic drug approve launch patent litigation ongoing congress fda actively consider way develop regulatory mechanism allow regulatory approval biologic drug similar generic copy innovative drug basis extensive datum require bla result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa ema ema evaluates maa provide recommendation european commission approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously table content product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity canada canada medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration currently unlike canada patent term restoration compensate patent term lose regulatory review process canada biologics generally treat chemicallysynthesized product respect patent right regulatory exclusivity health canada issue draft guidance outline additional information provide subsequent entry biologic know biosimilar product generic biologic order review application marketing approval rest world country outside japan canada wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor marketing distribution customer promote product medical journal directly healthcare provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos government agency market directly consumer directtoconsumer print radio television table content advertising addition sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint sale marketing organization explain approve use advantage product medical professional work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list demonstrate quality treatment benefit product marketing prescription pharmaceutical limit approve use particular product continue develop information product provide information response unsolicite inquiry doctor medical professional operation include marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist key primary care physician product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation business inventory management agreement ima substantially direct wholesaler distributor customer allow monitor wholesaler inventory level require wholesaler maintain inventory level month demand ima year term december subject certain termination provision competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label service research development new product process sale product impact new study indicate competitor product great safety andor efficacy profile treat disease particular form disease product sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale generic competition big competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far research development researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion sale product short period time rate sale decline product expiration exclusivity vary country general decline market rapid develop country recently observe rapid decline number country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture table content certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment manage care organization growth mcos major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator healthmaintenance organization medicare formulary alliance hospital physicians physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical trial demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually business impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval table content federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion discussion recent settlement certain investigation drug pricing sale marketing activity item financial statementsnote legal proceeding contingency fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth oig guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval approval ema obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limited operation profit price control plan operation reference price system germany company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available table content national market additionally member states regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow recent year congress state legislature consider number proposal enact law effect major change healthcare system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose similar cost containment issue exist foreign country business federal state government pursue direct method reduce cost drug pay participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate prime vendor program government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase prime vendor program participate provide discount outpatient medicine purchase certain public health service entity hospital meet certain criterion discussion rebate program item management discussion analysis financial condition result operationsnet sale critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital outofpocket expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing government regulation price constraint pharmaceutical manufacturing facility require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product line change year expect modify exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation february purchase acre site locate large scale multiproduct bulk biologic manufacturing facility deven massachusetts construction deven massachusetts facility begin early substantially complete expect submit site regulatory approval commercial production biologic compound anticipate begin later year rely party manufacture supply active ingredient necessary manufacture certain product include plavix baraclude avalide reyataz abilify erbitux sustiva franchise orencia onglyza maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt additional protection case step maintain approve backup source available example rely combine capacity deven massachusetts syracuse new york manati puerto rico facility capacity available thirdparty contract manufacturer manufacture orencia commercial quantity investigational biologic compound latestage development compound receive regulatory approval thirdparty manufacturer rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic business performance prospect table content negatively impact additionally thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain qualityassurance procedure relate quality integrity technical information production process control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material labeling perform test stage production process final product ensure product meet regulatory requirement standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system subsidiary thirdparty supplier environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis expend approximately million million capital project undertake specifically meet environmental requirement believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency table content employee december employ approximately people continue implement comprehensive cost reduction program include work force reduction rationalization facility splitoff mead johnson business employ approximately people discussion pti restructuring activity item financial statementsnote restructure foreign operation significant operation outside conduct subsidiary distributor geographic breakdown net sale table caption geographic area item financial statementsnote business segment information discussion net sale geographic area item management discussion analysis financial condition result operation geographic area international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product depend direction change relative dollar foreign currency value increase decrease report dollar value net asset result operation change foreign exchange rate net unfavorable impact growth rate revenue predict certainty future change foreign exchange rate effect attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statement note financial instrument bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march table content item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation face intense competition pharmaceutical manufacturer include innovative medicine lowerprice generic product competition manufacturer compete product include lowerpriced generic version product major challenge internationally business confront record level industry patent expiration increasingly aggressive generic competition competition include new product develop competitor low price superior performance feature competitive current product technological advance patent attain competitor iii result clinical study relate product competitor product earlierthanexpecte competition generic company business combination competitor major customer depend key product net sale cash flow earning derive majority revenue earning key product net sale plavix contribute approximately billion represent approximately total net sale net sale abilify contribute approximately billion represent approximately total net sale product avaproavalide reyataz sustiva franchise contribute billion net sale reduction sale key product significantly negatively impact net sale cash flow earning partnership net sales plavix europe asia contribute substantially equity net income affiliate million possible lose market exclusivity product early expect pharmaceutical industry majority innovative product commercial value usually realize period market exclusivity country market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category market exclusivity product base patent right andor certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain certain type patent andor licensor file market absent relevant patent protection product datum exclusivity period expire generic version product approve market generic clopidogrel bisulfate certain markets addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval possible publication certain study journal prior obtain marketing approval deem begin datum protection period product reduce expect term exclusivity manufacturers generic product increasingly seek challenge patent expire case choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation length market exclusivity product impossible predict certainty assurance particular product enjoy market exclusivity period time appear estimate disclose datum protection plavix expire plavix face competition european market datum protection plavix expire july generic clopidogrel bisulfate alternative form clopidogrel present half market include france germany end plavix experience significant market share erosion price discount market expect generic competition market begin half plavix net sale decrease significantly compare expect continue decline generic clopidogrel competition international net sale plavix equity net income affiliate expect significantly low compare prior year foreign law regulation negatively affect net sale profit margin subject new government law regulation healthcare reform initiative federal state level country change fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available certain foreign country new law regulation judicial governmental decision affect pricing reimbursement marketing jurisdiction change intellectual property law change tax law vii matter compulsory license alter protection afford product table content business result operation adversely affect pende healthcare reform legislation propose bill senate house representatives reform healthcare united states bill include provision increase medicaid rebate expand medicaid program provide additional prescription drug discount certain patient medicare andor assess annual fee pharmaceutical company thing congress fda actively consider way develop regulatory mechanism allow approval biologic drug similar generic copy innovative drug basis extensive datum basis bla healthcare reform bill pass law material adverse effect business result operation possible time predict certainty potential impact pende healthcare reform likely face increase pricing pressure abroad manage care organization institutional purchaser government agency program negatively affect net sale profit margin pharmaceutical product subject increase price pressure restriction worldwide include rule practice manage care organization institutional governmental purchasers judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general delay gain reimbursement andor reduction reimbursement amount country broad coverage pharmaceutical expenditure major european market japan canada developments technology andor industry practice directly indirectly impact reimbursement policy practice thirdparty payer change product label market product result certain study release product approve potentially negative impact sale product label pharmaceutical product change regulatory authority time include product market year change result additional datum postmarkete study headtohead trial spontaneous reporting adverse event patient healthcare professional study identify biomarker objective characteristic indicate particular response product therapy study produce important additional information product new information add product label affect safety risk andor efficacy benefit profile product additional information study identify portion patient population non responsive medicine change label base study limit patient population recent change plavix erbitux label study provide additional information sponsor sponsor competitor insurance company government institution manage care organization influential scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negative impact sale product extent patient population product label limited additionally certain study result especially headtohead trial affect product formulary listing adverse effect sale experience difficulty delay manufacture distribution sale product experience difficulty delay inherent manufacture distribution sale product seizure recall pharmaceutical product force closing manufacture plant supply chain continuity include result natural manmade disaster facility critical supplier vendor failure failure vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay consolidation rationalization manufacture facility sale closure certain site failure sole source single source supplier provide necessary raw material supply finish good extend period time impact continuous supply failure thirdparty manufacturer supply product timely base construction regulatory approval delay relate new facility expansion exist facility include intended support future demand biologic product vii manufacturing distribution problem include limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation business interruption impact continuous supply experience difficulty delay development commercialization new product experience difficulty delay development commercialization new product include inherent risk uncertainty associate product development compound product appear promise development fail reach market expect optimal timeframe fail reach market approve product extension additional indication number reason include efficacy safety concern delay denial necessary regulatory approval delay difficulty produce product commercial scale level excessive cost manufacture product failure enter successfully implement optimal alliance appropriate discovery andor commercialization product iii failure maintain consistent scope variety promise latestage product failure table content product achieve maintain commercial viability addition observe recent trend fda delay approval decision new product announce action date month long regulatory approval delay especially common product expect risk evaluation mitigation strategy address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product potentially negative impact net sale earning andor result significant impairment inprocess research development intangible asset finally natural man disaster sabotage research development lab loss key molecule intermediary negatively impact product development cycle legal matter adverse outcome negatively affect business currently involve lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute sale marketing practice internationally iii adverse decision litigation include product liability commercial case recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer result liability product pricing promotional matter vii lawsuit claim assert violation security antitrust federal state pricing law viii environmental health safety matter tax liability assurance increase scope matter additional lawsuit claim proceeding investigation future assurance matter material adverse impact rely party meet contractual regulatory obligation rely supplier vendor partner include alliance pharmaceutical company manufacture development commercialization product party meet contractual regulatory obligation relation arrangement failure party meet obligation andor development significant disagreement factor materially disrupt ongoing commercial relationship prevent optimal alignment partner activity material adverse impact addition party violate allege violate law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence failure execute business strategy adversely impact growth profitability year transform diversified pharmaceutical relate healthcare product company biopharmaceutical company focus innovative product area high unmet medical need risk associate strategy able consistently replenish innovative pipeline internal research development transaction party competition major pharmaceutical company acquisition product licensing opportunity intense eliminate opportunity make expensive able locate suitable acquisition target license partner reasonable price successfully execute transaction additionally change structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate inability expand product portfolio new product maintain competitive cost basis materially adversely affect future result operation addition failure hire retain personnel right expertise experience operation critical business function adversely impact execution business strategy increasingly dependent outsourcing arrangement increase dependence thirdparty provider certain outsource service include certain research development capabilitie certain financial outsource arrangement certain human resource function information technology activity system thirdparty provider locate market subject political risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure service provider meet obligation adequately deploy business continuity plan event crisis andor development significant disagreement natural man disaster factor materially disrupt ongoing relationship provider negatively affect operation increasingly dependent information technology increasingly dependent information technology system significant breakdown invasion destruction interruption system negatively impact operation addition risk business interruption reputational damage give infiltration datum center loss private information thirdparty provider table content adverse change global regional economic condition continue adverse effect profitability business global economic downturn adversely affect commercial activity region world business believe base current cash cash equivalent marketable security balance expect operating cash flow decrease liquidity credit market material impact liquidity cash flow financial flexibility deterioration financial market cause impairment investment portfolio negatively impact financial condition report earning continue decline economic activity adversely affect demand product reduce revenue earning cash flow passthrough effect result significant financial instability customer distributor alliance partner supplier critical vendor service provider counterpartie certain financial instrument marketable security derivative severe decline equity market result decline pension plan asset increase funding requirement global capital market stabilize partially recover future pension plan funding requirement continue sensitive global economic condition change foreign currency exchange rate interest rate material adverse effect result operation significant operation outside revenue operation outside account revenue expose change fluctuation foreign currency exchange rate significant borrowing expose change interest rate expose economic factor control illegal distribution sale party counterfeit version product steal product negative impact reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard product undergo patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell product addition theft inventory warehouse plant intransit properly store sell unauthorized channel adversely impact patient safety reputation business table content item unresolved staff comment item property world headquarter locate park avenue new york lease approximately square foot floor space lease approximately propertie country manufacture product worldwide location own manufacturing location aggregate square foot floor space geographic area follow december number location square feet united states europe middle east africa western hemisphere pacific total portion manufacturing location property own lease research development administration storage distribution information property item businessmanufacture quality assurance pti reduce expect continue reduce number manufacturing location item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december table content executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year james cornelius interim chief executive officer chairman board chairman board chief executive officer guidant corporation member management council interim chief executive officer director company chief executive officer director company present chairman board chief executive officer company lamberto andreotti executive vice president president worldwide director president chief operating officer pharmaceutical division company member management council executive vice president chief operating officer worldwide pharmaceutical division company executive vice president chief operating officer present president chief operating officer director company charle bancroft vice president finance worldwide pharmaceutical act chief financial officer division company member management council present act chief financial officer joseph caldarella present vice president corporate controller vice president corporate controller beatrice cazala president emea worldwide medicine international president global commercialization president europe president emea asia pacific worldwide medicine member management council international present president global commercialization president europe john celentano president health care group division company president emerge market asia pacific senior vice president strategy productivity member management council transformation present president emerge market asia pacific brian daniels senior vice president global clinical development research senior vice president global development medical affairs development division company member management council present senior vice president global development medical affairs carlo notaristefani president technical operation worldwide president technical operation global support function pharmaceutical division company member management council present president technical operation global support function table content anthony hooper president pharmaceuticals worldwide pharmaceutical president americas group division company member management council present president americas sandra leung vice president corporate secretary senior vice president general counsel corporate secretary vice president corporate secretary acting general member management council counsel present senior vice president general counsel corporate secretary anthony mcbride vice president human resources pharmaceutical senior vice president human resource commercial operation division company member management council present senior vice president human resources elliott sigal phd present chief scientific officer president research executive vice president chief scientific officer development president research development member management council robert zito present senior vice president corporate affairs senior vice president corporate business communication chief communication officer member management council table content item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse symbol bmy quarterly summary high low market price present common high low high low quarter second quarter quarter fourth quarter prefer quarter second quarter quarter fourth quarter second fourth quarter trade preferred stock holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february table content issuer purchase equity security follow table summarize surrender exchange equity security month period end december total number average price period share share january february march april june july august september october november december december month end december reflect transaction month end december surrender share common stock satisfy tax withholding obligation connection vest restricted stock issue employee december complete splitoff interest mead johnson tender shareholder splitoff complete exchange offer previously hold million share mead johnson million outstanding share stock june announce board director authorize purchase billion common stock december approximately billion share purchase program share repurchase pursuant program table content item select financial datum year financial summary amount million share datum income statement dataa net sale earning continue operation income taxis net earning continue operation attributable bristolmyer squibb company net earning continue operation common share attributable bristolmyer squibb company basic diluted average common share outstanding basic dilute dividend pay bms common preferred stock dividend declare common share financial position datum december total asset cash cash equivalent marketable securitiesb longterm debt equity recognize item affect comparability result discussion item year item management discussion analysis financial condition result operationsexpense marketable security include current noncurrent asset table content item management discussion analysis financial condition result operation executive summary bristolmyers squibb company refer bristolmyer squibb bms company global biopharmaceutical company consist global pharmaceuticalbiotechnology international consumer medicine business mission discover develop deliver innovative medicine help patient prevail disease license manufacture market distribute sell product global basis february mead johnson nutrition company mead johnson complete initial public offering ipo class common stock post ipo hold interest mead johnson december complete exchange offer previously hold million share mead johnson million outstanding share stock mead johnson financial result previously report separate segment report discontinued operation year present continued execute stringofpearl strategy acquisition medarex inc medarex september collaboration agreement enter year divestiture mead johnson continue execution stringofpearl strategy allow focused biopharmaceutical company meet productivity transformation initiative pti objective implement culture continuous improvement financial highlight follow table summary operating activity year end december dollar million share datum net sale biopharmaceutical segment result net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms dilute earning share continue operation attributable bms nongaap dilute earning share continue operation attributable bms cash cash equivalent marketable security net sale net sale increase exclude unfavorable foreign exchange impact net sale increase billion international net sale decrease increase exclude unfavorable foreign exchange impact billion sale growth lead continue increase plavix clopidogrel bisulfate abilify aripiprazole virology portfolio continue demonstrate strong sale growth lead baraclude entecavir sustiva efavirenz franchise reyataz atazanavir sulfate worldwide growth orencia abatacept sprycel dasatinib erbitux cetuximab net sale onglyza saxagliptin dppiv inhibitor submit regulatory authority country approve begin quarter launch country united state canada mexico germany united kingdom denmark net sale million table content biopharmaceutical segment result increase biopharmaceutical segment result attribute increase net sale key product note favorable gross margin percentage attribute favorable foreign exchange high average selling price favorable product mix realize efficiency pti efficient reduced spending marketing selling administrative partially offset increase investment research development pipeline net earning continue operation attributable bristolmyer squibb company increase attribute improve segment result partially offset unfavorable impact specify item prior year include gain sale imclone system incorporate imclone share additional taxis high income level effective tax rate reduce basis point net earning discontinue operation attributable bristolmyer squibb company complete splitoff mead johnson result aftertax gain approximately billion result mead johnson business relate gain include discontinue operation year present addition result mead johnson result include billion aftertax gain divestiture convatec million aftertax loss divestiture medical imaging operating result prior divestiture dilute earning share continue operation dilute earning share ep continue operation increase improved operating result drive activity discuss eps impact million share reduction result mead johnson splitoff minimal relatively short period low share count outstanding nongaap financial measure include nongaap earning continue operation relate eps information adjust exclude certain cost expense gain loss specify item nongaap dilute ep continue operation increase adjust specify item million million detailed listing specify item information reconciliation nongaap financial measure specify item nongaap financial measure cash cash equivalent marketable security source cash cash equivalent marketable security include billion generate operating activity net proceed mead johnson issuance note draw credit facility billion repay intercompany loan prior splitoff net proceed million mead johnson ipo proceed million sale mature business trademark source adequate fund dividend payment billion medarex business acquisition billion capital expenditure million business environment conduct business primarily pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect sale product include product efficacy safety price costeffectiveness marketing effectiveness product label quality control quality assurance manufacturing operation research development new product successfully compete business healthcare industry demonstrate product offer medical benefit cost advantage currently new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future manufacture brand product price high generic product generic competition lead challenge globally pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent subject new compete product form generic brand exclusivity loss lose major portion product sale short period time currently generic version biological product approve law table content law change future absence new legislation food drug administration fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologics manufacturing involve complex process costly traditional pharmaceutical operation internationally healthcare industry subject governmentimposed regulation authorize price price control continue impact net sale congress state legislature consider number proposal enact law result major change current healthcare system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose addition medicare prescription drug improvement modernization act provide outpatient prescription drug coverage senior citizen legislation modest favorable impact result increase number senior drug coverage time continue potential negative impact biopharmaceutical business result pricing pressure control market outside operate environment governmentmandate cost containment program regulatory body group exert downward pressure pricing pricing freedom limited instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available country growth manage care organization mcos play large role competition surround healthcare industry mco seek reduce healthcare expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important strategy company compete inclusion mco formulary generally successful major product include believe development manage care industry include continued consolidation continue generally downward pressure price pharmaceuticalbiotechnology production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic large percentage product portfolio continue arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale investment new stateoftheart manufacturing facility production biologic devens massachusetts construction substantially complete expect submit site regulatory approval maintain competitive position market strive uphold position dependent success discover develop deliver innovative costeffective product help patient prevail disease subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy continue execute multiyear strategy allow transform nextgeneration biopharmaceutical company strategy encompass aspect geography business yield continue yield substantial cost saving cost avoidance increase financial flexibility advantage attractive market opportunity arise completion mead johnson splitoff prior year disposition convatec medical imaging business operate core biopharmaceutical business focus complete sale mature brand business relate manufacturing facility asia pacific region china pakistan egypt australia reduce number facility global manufacturing network allocate resource continue stringofpearl strategy enable strategic transaction range collaboration license agreement acquisition company september complete acquisition medarex enter restructure collaboration agreement company include alder pharmaceuticals inc alder otsuka pharmaceutical ltd otsuka zymogenetics inc zymogenetics eli lilly company lilly january table content manage cost overall strategy implement pti initiative result incurrence billion cost target create total billion annual productivity saving cost avoidance approximately expect realize end subsequent pti implement strategic process design achieve culture continuous improvement enhance efficiency effectiveness competitiveness continue improve cost base continue focus development biopharmaceutical business maintain growth invest research development key growth product include specialty biologic medicine cardiovascular metabolic drug onglyza submit regulatory authority country approve begin quarter launch country canada mexico germany denmark refine focus emerge market represent significant opportunity growth identify emerge market focus brazil russia india china turkey emerge public health interest country good align strategy current portfolio pipeline product pipeline development belatacept september announce fda accept file review submission biologic license application belatacept development use kidney transplantation prescription drug user fee act pdufa goal fda action january fda announce cardiovascular renal drug advisory committee plan meet march provide advice application belatacept investigational costimulation blocker study use solid organ transplantation subject company sponsor clinical presentation include phase iii data american transplant congress datum suggest belatacept represent promise therapeutic option kidney transplant patient dapagliflozin october announce result week phase iii clinical study demonstrate investigational drug dapagliflozin add metformin provide significant mean reduction primary endpoint glycosylate hemoglobin level hbac secondary endpoint fast plasma glucose patient type diabete inadequately control metformin compare placebo plus metformin study show individual receive dapagliflozin statistically great mean reduction body weight compare individual take placebo june american diabetes association annual scientific session week study dapagliflozin present demonstrate improved glycemic control inadequately control type diabetes patient treat high dose insulin common oral antidiabetic medicine march company astrazeneca plc astrazeneca publish finding week phase iib doserange study dapagliflozin produce clinically meaningful reduction key glycemic measure study treatmentnaive type diabetes patient compare placebo study finding show patient receive dapagliflozin experience great reduction body weight compare patient placebo apixaban december company pfizer inc pfizer announce plan submit regulatory filing half apixaban europe company plan file regulatory approval apixaban prevention venous thromboembolism orthopedic surgery application support advance advance clinical trial evaluate apixaban versus european dose regimen enoxaparin prevention vte patient undergo orthopedic surgery apixaban novel oral highlyselective factor inhibitor new class agent study potential prevent treat blood clot vein artery july result apixaban advance study present latebreake clinical trial session congress international society thrombosis hemostasis studys result demonstrate apixaban superior european regimen enoxaparin standard care reduce risk venous thromboembolism patient undergo total knee replacement surgery show lower observed bleed rate compare enoxaparin study show overall safety profile apixaban similar enoxaparin march company pfizer initiate phase iii program treatment acute coronary syndrome table content ipilimumab company medarex announce american society clinical oncology annual meeting update survival result followup extension phase study twoyear survival range patient advance metastatic melanoma stage iii ntc march announce global collaboration nissan chemical industries ltd teijin pharma limited nissan development commercialization ntc selective inhibitor acetylcholineactivate potassium ion channel currently phase development japan maintenance normal sinus rhythm patient atrial fibrillation peginterferon lambda november annual meeting american association study liver disease company zymogenetic present final phase result peginterferon lambda hepatitis antiviral activity see dose level test result support move doserange phase study treatmentnave hepatitis patient january announce global collaboration zymogenetic peginterferon lambda novel type interferon currently phase development treatment hepatitis april company zymogenetic announce positive week result peginterferon lambda ribavirin treatment hepatitis ongoing phase clinical trial october company exelixis inc exelixis report new phase data developmental compound patient glioblastoma multiforme gbm common aggressive form brain cancer show promise activity gbm patient receive daily dose milligram compound company exelixis report american society clinical oncology annual meeting encourage datum ongoing phase trial patient previouslytreate gbm abilify november company otsuka announce fda approve abilify treatment irritability associate autistic disorder pediatric patient age year november company otsuka follow discussion committee medicinal product human use chmp withdrew marketing authorization application new indication abilify treatment major depressive episode adjunctive therapy patient inadequate response previous treatment antidepressant erbitux september european cancer organisation european society medical oncology multidisciplinary congress datum present phase iii erbitux study firstline metastatic colorectal cancer patient retrospective analysis phase iii crystal study demonstrate erbitux add folfiri chemotherapy regiman show increase progressionfree survival pfs median overall survival firstline metastatic colorectal cancer mcrc patient compare receive folfiri subset patient mcrc tumor kra mutation commonly refer wildtype kras median overall survival increase month patient receive erbitux plus folfiri compare month take folfiri phase iii study erbitux plus chemotherapy primarily capecitabine plus oxaliplatin firstline mcrc know coin conduct medical research council coin study meet primary endpoint overall survival july company lilly announce fda approve revision prescribe information erbitux concern treatment patient epidermal growth factor receptor egfrexpresse mcrc labeling revision include modification state erbitux recommend patient tumor kra mutation codon estimate patient mcrc tumor kras mutation approximately patient mcrc tumor kras mutation march company lilly announce company receive complete response letter fda firstline squamous cell carcinoma head neck supplemental biologic license application sbla erbitux complete response letter fda request additional pharmacokinetic study confirm comparability erbitux table content firstline head neck submission compare erbitux currently market united states previously announce company lilly recently withdraw advanced nonsmall cell lung cancer sbla erbitux matter case company continue work fda confirm pharmacokinetic comparability ixempra march withdraw marketing authorization application ixempra ixabepilone submit european medicine agency september ald november company alder enter global agreement development commercialization ald novel biologic complete phase iia development treatment rheumatoid arthritis ald humanize monoclonal antibody target plavix november plavix label update new warning use prilosec omeprazole certain drug interfere plavix reduce effectiveness label update include warning variability response attribute cyp genetic polymorphism company sanofi currently discussion fda possible additional change plavix label august oasis study group present initial result currentoasis clinical trial european society cardiology congress barcelona largescale global study provide information intensify doseregimen plavix acute coronary syndrome acs patient manage early invasive strategy intent percutaneous coronary intervention pci study show add benefit composite primary endpoint cardiovascular death heart attack stroke day higher dose entire acs study population clinically relevant subgroup prespecifie preliminary analysis pci group trial population potentially medically relevant difference patient outcome observe subgroup analysis show improvement outcome pci patient take high plavix dose regimen load day days standard dose regimen load day show reduction composite endpoint cardiovascular death heart attack stroke statistically significant increase primary safety endpoint major bleeding highdose compared standarddose plavix regiman overall trial population pci population march company sanofiaventis sanofi announce new finding active trial investigational study plavix provide result demonstrate patient atrial fibrillation increase risk stroke oral anticoagulant take plavix addition aspirin significantly reduce major vascular event aspirin great benefit reduction stroke primary goal physician treat patient atrial fibrillation compare aspirin take plavix addition aspirin significantly expect increase rate major bleed onglyza december company astrazeneca submit application food drug administration fda fix dose combination onglyza plus metformin hcl extendedrelease tablet fda currently review submission october company astrazeneca announce european commission grant marketing authorization onglyza dipeptidyl peptidase inhibitor country european union treat type diabete adult metformin sulfonylurea thiazolidinedione agent diet exercise provide adequate glycemic control october company astrazeneca announce result week phase iiib study adult type diabete inadequate glycemic control metformin therapy find addition onglyza day metformin treatment achieve primary objective demonstrate noninferiority compare addition januviasitagliptin day metformin treatment reduce hbac baseline july company astrazeneca announce fda approve onglyza onglyza indicate adjunct diet exercise improve blood sugar glycemic control adult treatment type diabete mellitus onglyza daily combination commonly prescribe oral antidiabetic medication metformin sulfonylureas thiazolidinedione monotherapy significantly reduce glycosylate hemoglobin level table content june american diabetes association annual scientific session interim analysis week month longterm phase iii extension study present show onglyza add metformin patient inadequately control type diabetes profile adverse event consistent see week treatment regiman produce longterm glycemic improvement orencia january european commission approve orencia combination methotrexate treatment moderate severe active polyarticular juvenile idiopathic arthritis pediatric patient year age old insufficient response disease modify antirheumatic drug include tnf inhibitor october announce new clinical datum support continue development subcutaneous administration orencia patient moderate severe rheumatoid arthritis subcutaneous program utilize new formulation orencia specifically design subcutaneous administration datum month openlabel trial involve patient present american college rheumatology annual scientific meeting study show weekly administration subcutaneous dose orencia result minimal transient immunogenicity prior month repeat dose immunogenicity similar orencia administer combination methotrexate common treatment rheumatoid arthritis monotherapy month patient antibody response subcutaneous orencia october announce twoyear result study support use orencia methotrexatenave patient moderate severe rheumatoid arthritis equal year duration datum agree study compare patient treat orencia plus methotrexate versus patient treat methotrexate patient take orencia combination methotrexate achieve sustained low disease activity score month datum show orencia plus methotrexate inhibit radiographic progression rheumatoid arthritis improve physical function addition relieve pain swell fatigue safety profile openlabel period similar doubleblind period study august announce clinical datum add label orencia support use orencia patient moderate severe rheumatoid arthritis equal year duration efficacy safety datum support use orencia newtobiologic patient moderate severe rheumatoid arthritis june announce annual european congress rheumatology eular result study demonstrate consistent safety effectiveness seven year treatment rheumatoid arthritis patient inadequate response methotrexate sprycel december annual meeting american society hematology phase datum sprycel present suggest sprycel provide chronic myeloid leukemia cml patient rapid improve response currentlyavailable firstline treatment imatinib result phase iii headtohead trial call dasision sprycel imatinib mesylate firstline treatment cml expected announce half american society clinical oncology annual meeting present interim result phase sprycel study demonstrate sprycel potential treatment castrateresistant prostate cancer crpc phase iii study sprycel crpc currently ongoing announce fda grant approval sprycel treatment adult phase cml chronic accelerate myeloid lymphoid blast phase resistance intolerance prior therapy include gleevec imatinib mesylate reyataz november announce labeling update reyataz label medicine include longterm datum castle study show oncedaily regimen reyataz ritonavir combination therapy previously untreated adult patient infect hiv lead endure virologic response week treatment baraclude october annual meeting american association study liver disease announce week datum baraclude chronic hepatitis patient evidence decompensate cirrhosis patient population study baraclude demonstrate great viral suppression compare adefovir table content result operation result continue operation exclude result relate mead johnson business prior splitoff december convatec business prior divestiture august medical imaging business prior divestiture january business segregate continue operation include discontinue operation year present discontinued operation result continue operation follow year end december change change dollar million net sale total expense earning continue operation income taxis net sale provision income taxis effective tax rate net earning continue operation net sale attributable noncontrolle interest net sale attributable bristolmyer squibb company net sale net sale composition change net sale follow year end december net sale analysis change analysis change dollar foreign foreign million total change volume price exchange total change volume price exchange nonus total key product contribute growth net sale plavix abilify represent total net sale contribute total growth net sale respectively plavix abilify represent total net sale contribute total growth net sale respectively international net sale decrease increase impact fluctuate value dollar foreign currency compare previous period exclude foreign exchange international net sale increase growth key product include baraclude hiv portfolio sprycel abilify orencia offset decrease plavix net sale stem increase generic competition report international net sale include copromotion sale report alliance partner sanofi plavix avaproavalide decrease generic competition net sale mature brand business divest represent approximately total net sale detail domestic international key product net sale discuss general business seasonal information pharmaceutical prescriber demand reference table estimated endus demand set forth comparison change net sale estimate total prescription growth retail mail order customer certain key pharmaceutical new product nonu net sale categorize base location customer recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy table content reconciliation gross sale net sale significant category grosstonet sale adjustment follow year end december dollar millions gross sale grosstonet sale adjustment prime vendor chargeback cash discount manage healthcare rebate contract discount medicaid rebate sale return adjustment total grosstonet sale adjustment net sale grosstonet sale adjustment primarily function gross sale activity typically correlate current sale trend manage healthcare rebate contract discount medicaid rebate cash discount adjustment manage healthcare rebate contract discount medicaid rebate affect change sale mix contractual legislative discount rate grosstonet sale adjustment increase manage healthcare rebate contract discount increase primarily high plavix medicare sale increase contractual discount rate sale return decrease primarily low provision pravachol zerit partially offset increase provision sprycel mature brand drive high anticipate sale return increase grosstonet sale adjustment attribute increase provision pravachol drive high sale return previously estimate zerit loss exclusivity activity end balance significant category grosstonet sale reserve adjustment follow manage healthcare rebate woman infant prime vendor cash contract medicaid sale child dollar million chargeback discount discount rebate return adjustment wic rebate total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december center medicare medicaid services policy group approve revise calculation determine medicaid rebate year period impact revise calculation net overpayment medicaid rebate million increase sale return primarily attribute increase provision pravachol drive high retail sale return previously assume loss exclusivity zerit table content net sale key product represent total net sale follow table detail international net sale key product percentage change prior period foreign exchange impact compare prior period commentary detail reason significant variance key product provide change attributable foreign year end december change exchange dollar million cardiovascular plavix nonus total avaproavalide nonus total virology reyataz nonus total sustiva franchise total revenue nonus total baraclude nonus total oncology erbitux nonus total sprycel nonus total ixempra nonus total neuroscience abilify nonus total immunoscience orencia nonu total metabolic onglyza nonus total change excess table content plavix platelet aggregation inhibitor alliance sanofi net sale increase primarily high average net selling price increase demand estimate total prescription demand increase international net sale decrease launch alternative salt form clopidogrel andor generic clopidogrel bisulfate half country august additional launch expect give widespread launch alternative salt form generic expect continue erosion sale impact international net sale equity net income affiliate item financial statementsnote legal proceeding contingenciesplavix litigation discussion plavix exclusivity litigation avaproavalide know aprovelkarvea angiotensin receptor blocker treatment hypertension diabetic nephropathy sanofi alliance net sale decrease primarily decrease estimate total prescription demand partially offset high average net selling price international net sale increase primarily high average net selling price partially offset unfavorable foreign exchange impact worldwide net sale increase primarily high average net selling price offset decline overall demand estimate total prescription demand decrease approximately reyataz protease inhibitor treatment hiv net sale increase primarily higher estimate total prescription demand high average net selling price international net sale increase primarily high demand markets europe key driver june approval firstline treatment sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate product sell joint venture gilead net sale increase primarily high demand high average net selling price estimate total prescription demand increase international net sale increase despite unfavorable foreign exchange impact primarily continued demand generate launch atripla canada fourth quarter baraclude oral antiviral agent treatment chronic hepatitis worldwide net sale increase primarily continue strong growth international market continues increase awareness acceptance longterm efficacy safety resistance datum evidence american association study liver disease treatment guideline recommend baraclude line treatment option erbitux monoclonal antibody design exclusively target block epidermal growth factor receptor express surface certain cancer cell multiple tumor type normal cell currently indicate use colorectal cancer head neck cancer erbitux strategic alliance lilly sell exclusively net sale decrease primarily study result release impact kra gene expression effectiveness patient colorectal cancer sale increase attributable increase demand indication usage treatment head neck cancer sprycel oral inhibitor multiple tyrosine kinase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec strategic alliance otsuka worldwide net sale increase primarily high demand previously launch market growth attribute recently launch market high average net selling price table content ixempra microtubule inhibitor treatment patient metastatic locally advanced breast cancer strategic alliance otsuka net sale increase reflect launch product october abilify antipsychotic agent treatment schizophrenia bipolar mania disorder major depressive disorder strategic alliance otsuka net sale increase primarily increase overall demand new indication certain patient bipolar disorder major depressive disorder high average net selling price increase partially offset million amortization million extension payment otsuka april estimate total prescription demand increase international net sale increase increase prescription demand aid new bipolar indication second quarter offset unfavorable foreign exchange impact orencia fusion protein indicate adult patient moderate severe rheumatoid arthritis inadequate response currently available treatment methotrexate antitumor necrosis factor therapy worldwide net sale increase primarily increase demand net sale increase primarily continued demand growth international net sale increase reflect product launch europe onglyza oncedaily oral tablet treatment type diabete onglyza submit regulatory authority country approve begin quarter launch countriesthe canada mexico germany denmark estimate prescription change datum provide report include information retail mail order channel reflect information channel hospital home healthcare clinic federal facility include hospital longterm care quarter change service provider prescription data wolter kluwer health inc supplier market research audit datum pharmaceutical industry external reporting purpose internal demand product prior prescription datum base generation prescription service version national prescription audit provide ims health im continuously seek improve quality estimate prescription change amount ultimate patientconsumer demand reviewing estimate calculation methodology process analyze internal thirdparty datum expect continue review refine methodology process calculation estimate continue review analyze party datum calculation estimate prescription datum base source prescription audit provide supplier product respective recordkeeping projection processes datum subject inherent limitation estimate base sampling include margin error calculate estimate total prescription change weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiply mail order prescription datum factor approximate add retail prescription believe calculation estimate total prescription change base weightedaverage approach provide superior estimate total prescription demand respect retail mail order channel use methodology internal demand reporting table content estimate endus demand follow table set forth key product sell year end december total net sales year change report net sale year iii estimate total prescription change retail mail order channel calculate base party datum weightedaverage basis month inventory hand wholesale distribution channel year end december december change change month total net sale net sale total prescription hand dollar million ims im plavix avaproavalide reyataz sustiva franchisea baraclude erbituxb sprycel ixemprabc abilify orenciab onglyzad sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla month hand relate sustiva erbitux ixempra orencia parenterally administer product prescriptionlevel datum physician write prescription product ixempra launch october onglyza launch august month hand ratio estimate divide estimate product wholesaler distribution channel estimate outmovement product wholesaler distribution channel period day change excess pursuant securities exchange commission sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception disclose product estimate level inventory distribution channel excess month hand december international product estimate level inventory distribution channel excess month hand september follow product meet criterion december onglyza type diabete product approximately month inventory hand inventory level hand product launch august september dafalgan analgesic product sell principally europe approximately month inventory hand direct customer compare approximately month inventory hand december level inventory hand primarily order pattern private pharmacist france september fervex cold flu product approximately month inventory hand direct customer compare approximately month inventory hand december increase level inventory hand primarily order pattern private pharmacist france initial stocking new distributor russia product sell exclusively wholesaler distributor determine month hand estimate information respect inventory level product hand outmovement product provide large wholesaler account approximately total gross sale product provide distributor factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process product sell exclusively wholesaler distributor business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case table content direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available develop variety methodology calculate estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly rely variety method estimate direct customer product level inventory calculate month hand business unit factor affect estimate include generic competition seasonality product direct customer purchase light price increase new product product presentation launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form geographic area general product available country world large market france japan spain canada italy germany china mexico net sale geographic area base location customer follow net sale change total net sale dollar millions united states europe middle east africa western hemisphere pacific total net sale increase primarily item previously discuss net sale net sale europe middle east africa decrease primarily unfavorable foreign exchange impact decrease net sale certain mature brand divestiture increase generic competition plavix partially offset sale growth major european market hiv portfolio baraclude abilify sprycel orencia net sale increase primarily sale growth major european market sprycel abilify hiv hepatitis portfolio favorable foreign exchange impact net sale western hemisphere country decrease primarily unfavorable foreign exchange impact partially offset increase net sale plavix avaproavalide orencia sprycel net sale essentially flat minimum foreign exchange impact net sale pacific region decrease primarily decrease net sale certain mature brand divestiture partially offset increase net sale baraclude sprycel favorable foreign exchange impact net sale increase primarily sale growth baraclude china japan korea favorable foreign exchange impact single country outside contribute total net sale combine net sale emerge market include brazil russia india china turkey approximate total net sale table content expense expense change net sale dollar million cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure litigation expense equity net income affiliate gain sale imclone share incomeexpense total expense change excess cost product sell cost product sell consist material cost internal labor overhead own manufacturing site thirdparty processing cost supply chain cost change foreign currency forward contract offset manufacture relate asset liability denominate foreign currency essentially cost manage primarily global manufacturing organization refer technical operation addition discovery royalty attribute license product connection alliance amortization milestone payment occur regulatory approval include cost percentage net sale vary period result product mix inflation cost attribute rationalization manufacturing site result accelerated depreciation impairment charge strand cost addition change foreign currency provide volatility give high percentage total cost denominate foreign currency improvement cost product sell percentage net sale drive favorable foreign exchange high average net selling price favorable product mix realize manufacturing efficiency pti offset high manufacturing cost attribute inflation cost include manufacture rationalization charge million primarily relate implementation pti compare million rationalization charge recognize improvement cost product sell percentage net sale primarily attribute favorable product sale mix high average net selling price realize manufacture saving pti factor partially offset high manufacturing cost attribute inflation cost include manufacture rationalization charge million primarily relate implementation pti compare million rationalization charge recognize marketing sell administrative marketing sell administrative expense consist employee salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost expense attribute product manufacturing cost research development expense expense manage regional commercialization function global function finance law information technology human resource decrease result favorable foreign exchange impact efficiency gain pti increase primarily relate million process standardization cost incur pti high average net selling expense support key product unfavorable foreign exchange impact advertising product promotion advertising product promotion expense consist related media sample direct consumer program decrease attribute reduced spending promotion product near patent expiration favorable foreign exchange impact partially offset increase spend onglyza launch pipeline product increase primarily relate increase promotion new indication abilify increase promotion orencia unfavorable foreign exchange impact table content research development research development expense consist internal salary benefit cost thirdparty grant fee pay clinical research organization supply facility cost expense include thirdparty licensing fee typically pay upfront regulatory contractual milestone meet certain expense share alliance partner base contractual agreement approximately expense manage global research development organization historically approximately total spend attribute development activity remainder attribute preclinical research activity expense vary period number reason include time upfront license milestone payment increase attribute additional spending support mature pipeline compound obtain stringofpearl strategy offset favorable foreign exchange impact increase primarily relate increase upfront licensing milestone payment increase spending pipeline compound unfavorable foreign exchange impact increase partially offset share codevelopment cost alliance partner astrazeneca pfizer upfront license milestone payment expense research development million primarily attribute zymogenetic alder nissan million primarily attribute exelixis pdl biopharma inc kai pharmaceuticals inc million primarily attribute exelixis pfizer adnexus therapeutics inc adnexu isis pharmaceutical acquisition medarex result million additional spend acquire inprocess research development charge relate acquisition kosan biosciences inc kosan acquisition adnexu inprocess research development iprd project acquire business combination january capitalize initially consider indefinitelived asset provision restructure change provision restructure primarily attributable time worldwide implementation pti litigation expense expense primarily million security litigation settlement information item financial statementsnote legal proceeding contingency equity net income affiliate equity net income affiliate primarily related international partnership sanofi vary base international plavix net sale include partnership decrease attribute impact alternative salt form clopidogrel generic clopidogrel competition international plavix net sale commence unfavorable trend earning expect continue future period generic product launch half country august additional launch expect future year additional information item financial statementsnote alliance collaboration gain sale imclone share gain sale imclone share attribute receipt approximately billion cash tender investment imclone item financial statementsnote alliance collaboration detail table content incomeexpense incomeexpense include year end december dollar million interest expense interest income gain debt buyback termination interest rate swap agreement ar impairment foreign exchange transaction lossesgain gain sale product line business asset medarex acquisition net royalty income amortization upfront licensing milestone payment receive alliance partner pension settlementscurtailment incomeexpense interest expense decrease primarily low interest rate amortization result termination interest rate swap interest income decrease primarily low interest rate partially offset high cash cash equivalent marketable security balance auction rate security ar impairment charge recognize severity duration decline value future prospect issuer ability intent hold security recover value value ars december million future decline fair value consider temporary recognize result operation impact foreign exchange mainly sudden dramatic strengthen dollar second half generate significant gain foreign currency dominate transaction recognize less extent earning impact period foreign exchange hedge discontinue qualify cash flow hedge item financial statementsnote financial instrument gain sale product line businesse asset primarily relate sale mature brand include business indonesia australia business egypt sale bufferin excedrin brand japan asia exclude china certain oceanic country net royalty alliance partner activity include income earn sanofi partnership amortization certain upfront licensing milestone payment relate alliance pension settlement curtailment primarily attribute amendment eliminate credit future benefit relate service pension plan participant effective january amendment result curtailment charge million remainder charge result high level lump sum payment certain plan exceed threshold sum plan interest cost service cost require settlement accounting result acceleration portion previously defer actuarial loss activity drive pti certain divestiture additional charge recognize future particularly pension plan low threshold result elimination service cost item financial statementsnote pension postretirement postemployment liability detail include gain loss sale property plant equipment convatec medical imaging net transitional service fee table content specify item follow specify item affect comparability result period present item exclude segment result marketing year end december cost sell research provision product litigation income dollar million sell administrative development restructure expense expense total productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale product line business asset total pti litigation charge accelerate depreciation bms foundation funding initiative loss sale investment upfront license milestone payment medarex acquisition debt buyback swap termination product liability total income taxis item decrease net earning continue operation acquire marketing inprocess gain year end december cost sell research research provision sale product litigation imclone income dollar million sell administrative development development restructure expense share expense total productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale leaseback property termination lease contract gain sale product line business total pti litigation settlement insurance recovery product liability upfront licensing milestone payment acquire inprocess research development asset impairment ar impairment loss sale debt buyback swap termination gain sale imclone share total income taxis item decrease net earning continue operation table content acquire marketing inprocess year end december cost sell research research provision product litigation income dollar million sell administrative development development restructure expense expense total productivity transformation initiative downsize streamline worldwide operation accelerate depreciation shutdown cost process standardization implementation cost total pti litigation settlement insurance recovery product liability upfront licensing milestone payment acquire inprocess research development ar impairment downsize streamline worldwide operation accelerate depreciation asset impairment contract termination gain sale property product line business total income taxis item change estimate taxis prior year specify item decrease net earning continue operation table content nongaap financial measure nongaap financial measure include nongaap earning continue operation relate eps information adjust exclude certain cost expense gain loss specify item information intend enhance investor overall understanding past financial performance prospect future example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap item gaap measure exclude purpose determine adjusted earning adjust measure charge relate implementation pti gain loss purchase sale business product line investment discontinue operation restructure exit cost accelerate depreciation charge asset impairment charge recovery relate significant legal proceeding upfront license milestone payment inlicense product achieve regulatory approval immediately expense iprd charge prior special initiative funding bristolmyers squibb foundation significant tax event detail list item exclude nongaap earning continue operation specify item similar charge gain item recognize prior period reasonably possible reoccur future period reconciliation gaap nongaap follow year end december year end december specify specify dollar million share datum gaap item nongaap gaap item nongaap net earning continue operation attributable bms contingently convertible debt interest expense dividend undistribute earning attributable unvested share net earning continue operation attributable bms diluted eps calculation average common share outstandingdilute diluted ep continue operation attributable bms segment result segment result consistent financial information regularly review chief operating decision maker purpose evaluate performance allocate resource set compensation target planning forecast future period segment result exclude impact specify item significant indicative current operating performance ongoing result follow table reconcile segment result earning continue operation income taxis segment result change net sale dollar million biopharmaceutical specify item noncontrolle interest earning continue operation income taxis earning increase primarily increase net sale key product favorable gross margin price increase product mix realize efficiency previous pti initiative efficient spending marketing sell administrative expense partially offset increase investment research development pipeline improve gross margin rate efficiency mention result increase segment result express percentage net sale past year table content income taxis effective income tax rate earning continue operation income taxis compare effective income tax rate low statutory rate decision permanently reinvest earning certain manufacturing operation ireland puerto rico switzerland offshore federal research development tax credit additional information critical accounting policy item financial statementsnote income taxis decrease effective tax rate primarily unfavorable tax impact relate iprd ar impairment charge less extent high benefit relate certain contingent matter increase effective tax rate primarily high pretax income include gain sale imclone share earning mix high tax jurisdiction partially offset factor low nondeductible charge iprd low ar impairment charge little tax benefit tax rate favorably impact benefit million tax relate final settlement audit internal revenue service irs tax rate unfavorably impact impairment investment certain ar little tax benefit nondeductible writeoff iprd relate acquisition adnexus partially offset tax benefit million quarter favorable resolution certain tax matter irs relate deductibility litigation settlement expense foreign tax credit claim discontinued operation december complete splitoff remain interest mead johnson mean exchange offer bms shareholder august complete divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partner avista january complete divestiture bristolmyers squibb medical imaging medical imaging avista item financial statementsnote discontinue operation noncontrolle interest noncontrolle interest primarily relate partnership sanofi territory cover america relate plavix net sale item financial statementsnote alliance collaboration increase noncontrolle interest correspond increase net sale plavix net earning discontinue operation attributable noncontrolle interest primarily relate mead johnson own public prior splitoff summary noncontrolle interest follow year end december dollar million sanofi partnership noncontrolle interestpretax income taxis net earning continue operation attributable noncontrolle interestnet taxis net earning discontinue operation attributable noncontrolle interest net taxis net earning attributable noncontrolle interestnet taxis table content financial position liquidity capital resource maintain significant level work capital approximately billion december billion december future period expect cash generate operation exist cash cash equivalent marketable security borrowing capital market sufficient cover cash need work capital capital expenditure strategic alliance acquisition milestone payment dividend pay cash cash equivalent marketable security conversion work capital item borrowing expect fund nearterm operation outside believe base current level cash cash equivalent marketable security financial asset expect operate cash flow current downturn global economic activity material impact liquidity cash flow financial flexibility ability fund operation include dividend billion year revolve credit facility syndicate lender mature december extendable consent lender facility contain customary term condition include financial covenant ratio consolidate net debt consolidated capital exceed end quarter compliance covenant inception facility borrowing outstanding facility december net cash position december follow dollar million cash cash equivalent marketable securitiescurrenta marketable securitiesnoncurrentb total shortterm borrowing include current portion longterm debt longterm debt total debt net cash position include million float rate security frs security december include million million ar frs security december respectively begin second quarter diversified investment portfolio acquire noncurrent marketable security include purchase corporate debt security investment subject change fair value result interest rate fluctuation market factor impact result operation investment policy place limit investment time maturity investment institution policy require investment highly rate corporate financial institution item financial statementsnote cash cash equivalent marketable security additional source liquidity sell trade account receivables principally nonus government hospital customer party receivables sell nonrecourse basis approximate million million respectively sale agreement allow recourse event uncollectibility retain interest underlie asset sell cash cash equivalent marketable security hold outside approximately billion december utilize fund nonus operation repatriate taxis previously provide cash repatriation subject restriction certain jurisdiction subject withholding taxis credit rating moodys investor service moodys longterm shortterm credit rating currently prime respectively moodys revise longterm credit outlook negative stable august standard poor longterm shortterm credit rating currently respectively sps long term credit rating remain stable outlook fitch rating fitch longterm shortterm credit rating currently respectively fitchs longterm credit rating remain stable outlook credit rating consider investment grade rating designate longterm security low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm obligation strong capacity timely repayment table content cash flow follow discussion cash flow activity december dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt cash disbursement relate activity invest activity financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item depreciation amortization impairment charge stockbase compensation charge gain loss attribute invest financing activity gain loss sale product line business change operate asset liability reflect time difference receipt payment cash associate transaction recognize result operation net impact change operate asset liability aggregate net cash inflow million cash inflow million cash outflow million item include impact change receivables inventory defer income account payable income taxis receivablepayable operating asset liability discuss detail continue maximize operate cash flow work capital initiative design continue improve work capital item directly affect change sale volume receivables inventory account payable improvement drive action include additional factoring nonus trade receivables revise contractual payment term customer vendor enhance collection process supply chain initiative design optimize inventory level progress area monitor period component annual incentive plan follow summarize certain work capital component express percentage trail month net sale december amount include mead johnson splitoff december trail trail december month december month dollar million net sale net sale net trade receivables inventory account payable total change operate asset liability aggregate net cash inflow million include cash inflow account payable million primarily attribute timing payment vendor alliance impact work capital initiative discuss cash inflow receivables million primarily attribute additional factoring nonus trade receivables japan spain cash inflow defer income million mainly milestone payment receive pfizer million astrazeneca million partially offset amortization cash outflow operate asset liability million primarily relate pension funding excess current year expense million payment otsuka amortize reduction net sale extension period million table content change operate asset aggregate net cash inflow million include cash inflow income tax payablereceivable million include impact receipt million tax refund include interest relate prior year foreign tax credit carryback claim cash inflow account payable million primarily attribute time vendor alliance payment cash inflow inventory million primarily attribute utilization inventory build prior year new product launch strategic build exist product launch include new indication abilify cash inflow defer income million primarily receipt upfront license milestone payment alliance partner cash outflow account receivables million attribute increase sale cash outflow operate asset liability million primarily net litigation relate payment million attribute settlement certain pricing sale litigation accrue prior period pension funding excess current year expense million increase noncurrent inventory million change operate asset aggregate net cash outflow million include cash outflow account receivable million primarily attribute increase sale cash outflow foreign income taxis payable million primarily attribute tax payment include settlement payment associate tax issue irs audit cash inflow defer income million primarily receipt upfront license milestone payment alliance partner include pfizer astrazeneca cash inflow account payable million include impact increase purchase raw material plan inventory buildup cash inflow operate asset liability million primarily increase accrue royalty attribute increase plavix net sale increase accrue salary bonus timing payment partially offset cash outflow primarily relate litigation relate payment million settlement pricing sale litigation accrue prior period investing activity net cash investing activity billion include acquisition medarex billion net cash acquire million net purchase marketable security billion capital expenditure million mead johnson cash include splitoff million proceed sale business investment include business asiapacific region million australia million proceed sale genmab celldex security million net cash provide investing activity billion include proceed divestiture convatec billion medical imaging million proceed tender share imclone billion proceed sale leaseback paris france facility million proceed sale business include mature brand business egypt million capital expenditure million include expenditure associate construction biologic facility deven massachusetts acquisition kosan million table content net cash investing activity million include capital expenditure million acquisition adnexu million net proceed sale marketable security million proceed sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic countrie dermatology product million financing activity net cash financing activity million include dividend payment billion repayment mead johnson revolving credit facility million early extinguishment certain debt security million net proceed issuance mead johnson note billion revolve credit facility million net proceed mead johnson ipo million net proceed termination interest rate swap agreement million net proceed exercise stock option million net cash financing activity billion include dividend payment billion redemption float rate convertible senior debenture billion repayment note august million yen note million repurchase note million net proceed issuance note million note billion net proceed termination interest rate swap agreement million net proceed stock option exercise million reflect exercise few stock option decrease average stock price compare prior period net cash financing activity billion include dividend payment billion repayment float rate bank facility billion proceed exercise stock option million dividend declare common share december declare quarterly dividend common share expect pay dividend year share dividend decision quarterly basis board director table content contractual obligation payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debtb operating lease purchase obligation uncertain tax positionsc longterm liabilities totald current portion longterm debt obligation include shortterm borrowing balance approximate outstanding nominal longterm debt value include estimate future interest payment shortterm longterm debt security include accrue interest payable recognize consolidated balance sheet consist primarily accrual interest shortterm longterm debt accrual periodic cash settlement derivative net counterparty uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table item financial statementsnote income taxis detail table exclude future contribution pension postretirement postemployment benefit plan require contribution contingent numerous factor include minimum regulatory funding requirement fund status plan uncertainty future obligation exclude table contribution international plan expect million item financial statementsnote pension postretirement postemployment liability detail addition commit approximately billion aggregate potential future research development milestone payment party inlicense development program early stage milestone define milestone achieve phase iii clinical trial comprise billion total commit late stage milestone define milestone achieve post phase iii clinical trial comprise billion total commit payment agreement generally payable achievement certain developmental regulatory milestone specific timing predict achievement milestone probable reasonably estimable contingency recognize addition certain royalty obligation calculate percentage net sale agreement provide salesbased milestone aggregate approximately billion obligate pay alliance partner achievement certain sale level discussion contractual obligation item financial statementsnote pension postretirement postemployment liability note short term borrowing longterm debt note financial instrument note lease sec consent order previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis table content maintain inventory management agreement imas pharmaceutical wholesaler account nearly total gross sale biopharmaceutical product current term ima large wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product wholesaler currently account approximately total gross sale biopharmaceutical product inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level biopharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast biopharmaceutical business outside significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent recently issue accounting standard follow new accounting standard discuss item financial statementsnote accounting policiesrecently issue accounting standard asu multipledeliverable revenue arrangement consensus fasb emerge issue task force amendment asc emerge issue task force eitf issue revenue arrangement multiple deliverable issue october effective reporting period begin june asu accounting transfer financial asset amendment asc sfa accounting transfer financial asset amendment fasb statement issue june codify issue asu december adopt january asu improvements financial reporting enterprise involve variable interest entity amendment asc sfas amend fasb interpretation issue june codify issue asu december adopt january asc statement financial standard sfas hierarchy generally accept accounting principle issue july effective adopt september asc fair value measurement disclosure sfas fair value measurement adopt nonfinancial asset liability january asc noncontrolling interest consolidate financial statementsan amendment arb sfas noncontrolle interest consolidate financial statementsan amendment arb adopt january asc sfa business combination adopt january asc collaborative arrangement eitf issue accounting collaborative arrangement relate development commercialization intellectual property effective january apply retroactively critical accounting policy prepare financial statement conformity accounting principle generally accept preparation financial statement conformity generally accept accounting principle gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period critical accounting policy important financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate accounting policy discuss audit committee board director table content revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management recognize revenue title substantially risk reward ownership transfer customer generally occur date shipment net grosstonet sale adjustment discuss involve significant estimate judgment discussion revenue recognition item financial statementsnote accounting policiesrevenue recognition sale rebate return accrual grosstonet sale adjustment follow significant category grosstonet sale adjustment prime vendor chargeback manage healthcare rebate contractual discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require use information external source net sale reconciliation gross sale net sale significant category grosstonet sale adjustment prime vendor chargeback business participate prime vendor program government entity significant department defense department veteran affair party pricing product extend wholesaler list price participate entity entity purchase product wholesaler low prime vendor price wholesaler charge difference acquisition cost low prime vendor price account prime vendor chargeback reduce account receivable equal estimate chargeback claim attributable sale determine estimate prime vendor chargeback primarily base historical experience prime vendor chargeback current contract price prime vendor program consider prime vendor payment level inventory distribution channel claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience cash discount certain country offer cash discount approximate sale price incentive prompt payment account cash discount reduce account receivable discount consider payment performance adjust accrual reflect actual experience manage healthcare rebate contract discount offer rebate discount manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization addition accrue rebate department defense tricare retail pharmacy refund program account manage healthcare rebate contract discount establish accrual equal estimate manage healthcare rebate contractual discount attributable sale determine estimate manage healthcare rebate contractual discount accrual primarily base historical experience rebate discount current contract price consider sale performance product subject manage healthcare rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience medicaid rebate business participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include medicaid rebate accrual consider medicaid rebate purpose discussion account medicaid rebate establish accrual equal estimate medicaid rebate claim attributable sale determine estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate consider outstanding medicaid claim medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience table content sale return account sale return establish accrual equal estimate sale recognize related product expect return return establish product determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product consider factor adjust accrual periodically quarter reflect actual experience event product recall product discontinuance consider reason impact action adjust sale return accrual appropriate taking account historical experience estimate level inventory distribution channel product discontinuance estimate continue demand sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product historical experience product similar therapeutic category reliably estimate expect return new product defer recognition revenue right return long exist develop sufficient historical experience estimate sale return consider shelf life new product determine adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product develop optimal manufacturing process new product lengthen shelf life addition high launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case assess reduce shelf life estimate level inventory distribution channel project demand determine adjustment sale return accrual appropriate adjustment addition grosstonet sale adjustment describe grosstonet sale adjustment example offer sale discount significantly nonus business offer consumer coupon rebate business addition number country outside include certain major european country provide rebate government entity generally account grosstonet sale adjustment establish accrual equal estimate adjustment attributable sale generally determine estimate accrual grosstonet sale adjustment primarily base historical experience performance commitment government entity relevant factor include estimate level inventory distribution channel adjust accrual periodically quarter reflect actual experience use information external source use information external source estimate grosstonet sale adjustment estimate inventory wholesaler base project prescription demandbase sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital effective january change service provider prescription datum supplier market research audit datum pharmaceutical industry project prescription demandbase sale biopharmaceutical product prior prescription datum base nextgeneration prescription service version national prescription audit provide im continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information table content retirement benefit pension plan postretirement benefit plan account actuarial valuation key assumption calculate cost pension benefit discount rate expect longterm rate return plan asset consultation actuary evaluate select key assumption calculate cost pension benefit salary growth retirement turnover healthcare trend mortality rate base expectation actual experience appropriate determine assumption remeasurement date include december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate use yield high quality corporate bond coincide cash flow plan estimate payout citigroup pension discount curve determine discount rate plan plan pension expense determine weighted average discount rate present value benefit obligation december plan determine discount rate discount rate determine plan pension expense reduce expense increase approximately million assumed discount rate determine project benefit obligation december reduce project benefit obligation increase approximately million determine expect longterm rate return plan asset estimate return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit item financial statementsnote pension postretirement postemployment liability business combination consolidate financial statement reflect acquire business completion acquisition asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill determine fair value intangible asset include iprd typically use income method method start forecast expect future net cash flow cash flow adjust present value apply appropriate discount rate reflect risk factor associate cash flow stream significant estimate assumption inherent income method method include timing project future cash flow time project cost develop iprd commercially viable product discount rate select measure risk inherent future cash flow assessment asset life cycle competitive trend impact asset include consideration technical legal regulatory economic barrier entry expect change standard practice indication address asset january acquire iprd project initially capitalize consider indefinitelived asset subject annual impairment review occurrence certain event compound reach commercialization asset amortize expect useful life prior january amount allocate acquire iprd expense date acquisition determine useful life intangible asset base period expect contribute future cash flow pertinent matter associate asset environment operate consider include legal regulatory contractual provision effect obsolescence demand competition economic factor table content medarex inc acquisition september acquire remain outstanding share medarex own approximately billion provide right ipilimumab increase biologic development pipeline item financial statementsnote medarex inc acquisition medarex biopharmaceutical company focus discovery development commercialization fully human antibodybased therapeutic product address major unmet healthcare need area oncology inflammation autoimmune disorder infectious disease approximately billion purchase price allocate estimate fair value identifiable intangible asset include iprd project approximately billion develop technology million compound reach commercialization asset amortize expect useful life fair value iprd include approximately billion assign ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma ongoing ipilimumab phase study lung cancer phase iii study adjuvant melanoma hormone refractory prostate cancer overall development effort estimate range complete project cost complete development effort range million million acquisition date fair value ipilimumab determined market participant view consider preexist term collaboration arrangement bms include cost profit sharing split project unit account global view significant delay obtain marketing approval ipilimumab inability bring ipilimumab market result iprd partially fully impair remain iprd assign project phase development project stage development generate medarex technology develop licensing partner generate milestone payment royalty commercialization significant judgment apply develop project cash flow include relative timing probability assume regulatory approval project cash flow assume initial positive cash flow commence shortly receipt expect regulatory approval subject trial result thing approve potentially early project cash flow discount actual cash flow attribute project likely different assumed ultimate realization iprd project depend successful regulatory approval receive market factor typical biopharmaceutical product develop technology attribute separate license arrangement receive regulatory approval technology platform produce high affinity fully human antibody use broad range therapeutic area include immunology oncology fair value license arrangement million determine base present value project royalty stream begin fair value technology platform million determine base expect annual number antibodie achieve early candidate nomination status develop technology amortize expect useful life year license arrangement year technology platform impairment goodwill goodwill test annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill consider impaired carrying reporting unit goodwill exceed estimate fair value base recent annual impairment test complete quarter fair value goodwill substantially excess relate carrying value discussion goodwill acquire inprocess research development intangible asset item financial statementsnote accounting policiesgoodwill acquire inprocess research development intangible asset indefinitelive intangible asset include iprd indefinitelive intangible asset subject amortization test impairment annually frequently event change circumstance indicate asset impair consider factor include stage development current legal regulatory environment competitive landscape consider industry success rate bring developmental compound market iprd impairment charge occur future period table content fix asset periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow report asset dispose low carrying value estimate net realizable value estimate future cash flow base reasonable supportable assumption projection require judgment change key assumption business prospect change market condition result impairment charge impairment charge longlive asset million million million discussion impairment longlive asset item financial statementsnote accounting policiesimpairment longlive asset marketable security investment company marketable security classify available sale report fair value change fair value report accumulate comprehensive income decline fair value consider temporary charge earning fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity determine security otherthantemporarily impair typically consider severity duration decline future prospect issuer ability intent hold security recovery decline fair value determine credit relate charge earning average cost method determine realize gain loss sale available sale security realize gain loss include incomeexpense level investment include frs ar utilize valuation model include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation subject uncertainty difficult predict utilize considerable judgment estimation factor impact valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity discussion current noncurrent marketable security frs ar item financial statementsnote fair value measurement note cash cash equivalent marketable security account own company ability exercise significant influence equity method accounting share net income loss equity investment include equity net income affiliate consolidated statement earning investment fair market value fall carry value assess decline temporary consider intent ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity impairment loss recognize incomeexpense decline market value deem temporary discussion marketable security investment company item financial statementsnote account policiesmarketable security investment company note alliance collaboration restructure restructuring charge recognize result action streamline operation rationalize manufacture facility significant judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate detailed discussion restructure item financial statementsnote accounting policiesrestructure note restructure table content contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative judgment subject change adjustment defer tax valuation allowance earning period assessment net defer tax asset billion billion december respectively net valuation allowance billion year recognize defer tax asset december relate federal net operating loss carryforward million federal foreign tax credit carryforward million federal research development tax credit carryforward million net operating loss carryforward acquire result acquisition medarex kosan adnexus subject limitation section internal revenue code net operating loss carryforward expire vary amount begin expiration foreign tax credit research development tax credit carryforward expire vary amount begin realization carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure believe likely defer tax asset realize prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion rely certain assumption representation covenant mead johnson future conduct business matter effect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement example mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset agree indemnify mead johnson certain taxis relate business prior completion ipo create restructure facilitate ipo establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know table content discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event table content item quantitative qualitative disclosure market risk expose market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure primary net foreign currency translation exposure euro japanese yen canadian dollar british pound australian dollar mexican peso chinese renminbi foreign currency forward contract manage exposure instrument generally qualify cash flow hedge accounting treatment manage consolidated basis efficiently net exposure advantage natural offset derivative instrument interest rate risk management strategy derivative instrument principally comprise fixedto float interest rate swap generally qualify fairvalue hedge accounting treatment addition financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant portion revenue earning cash flow expose change foreign currency rate use foreign currency forward contract manage foreign exchange risk primarily arise certain intercompany transaction designate derivative instrument foreign currency cash flow hedge appropriate addition expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency order manage risk use foreign currency forward contract offset exposure certain asset liability earning denominate certain foreign currency foreign currency forward contract designate hedge change fair value derivative recognize earning incomeexpense occur estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant increase decrease million fair value foreign exchange forward contract hold december realize effect earning remain life contract expose translation risk nonus dollardenominate net asset order manage risk use nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge recognize foreign currency translation component accumulate oci additional information item financial statementsnote financial instrument interest rate risk use interest rate swap interest rate risk management strategy interest rate swap principally fixedtofloate rate swap designate fairvalue hedge swap intend provide appropriate balance fix float rate debt estimate increase decrease basis point shortterm longterm interest rate decrease increase fair value interest rate swap million exclude effect counterparty credit risk realize affect earning remain life swap marketable security subject change fair value result interest rate fluctuation market factor policy invest highly rate institution place limit time maturity investment individual institution credit risk periodically sell nonus trade receivables mean reduce collectability risk sale agreement provide recourse event uncollectibility retain interest underlie asset sell monitor investment counterpartie objective minimize concentration credit risk investment policy place limit time maturity investment individual counterparty policy require investment highly rate corporate financial institution use derivative instrument expose credit risk fair value derivative instrument contract positive expose credit risk counterparty fail perform fair value derivative instrument contract negative counterparty expose credit risk fail perform obligation require post collateral derivative contract liability position require counterpartie post collateral derivative asset position seek minimize credit risk derivative instrument enter transaction reputable financial institution policy diversify derivative counterpartie mitigate overall risk counterparty default additional information item financial statementsnote fair value measurement note cash cash equivalent marketable security note shortterm borrowing longterm debt note financial instrument table content bristolmyer squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure litigation expense equity net income affiliate gain sale imclone share incomeexpense total expense earning continue operation income taxis provision income taxis net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning discontinue operation net earning net earning attributable noncontrolle interest net earning attributable bristolmyer squibb company amount attributable bristolmyer squibb company net earning continue operation net earning discontinue operation net earning attributable bristolmyer squibb company earning common share continue operation attributable bristolmyer squibb company basic diluted earning common share attributable bristolmyer squibb company basic dilute dividend declare common share accompany note integral consolidated financial statement table content bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation foreign currency translation reclassify net earning business divestiture foreign currency translation hedge net investment derivative qualify cash flow hedge net taxis derivative qualify cash flow hedge reclassify net earning net taxis derivative reclassify net earning business divestiture net taxis pension postretirement benefit net taxis pension postretirement benefit reclassify net earning net taxis pension postretirement benefit reclassify net earning business divestiture net taxis available sale security net taxis available sale security reclassify net earning net taxis total comprehensive incomeloss comprehensive income comprehensive income attributable noncontrolle interest comprehensive income attributable bristolmyer squibb company retain earning retain earning january cumulative effect adopt new accounting principle note net earning attributable bristolmyer squibb company cash dividend declare retain earning december accompany note integral consolidated financial statement table content bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory defer income taxis prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable total current liability pension postretirement postemployment liability defer income foreign income taxis payable liability longterm debt total liability commitment contingency note equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement table content bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity net earning attributable noncontrolle interest depreciation amortization defer income tax expensebenefit stockbase compensation expense acquire inprocess research development impairment charge gain related divestiture discontinue operation gain sale imclone share gainslosse change operate asset liability receivable inventory account payable deferred income foreign income taxis payable change operate asset liability net cash provide operating activity cash flow invest activity proceed sale marketable security purchase marketable security addition property plant equipment capitalize software proceed sale business property plant equipment investment proceed divestiture discontinued operation mead johnson cash splitoff purchase business net cash acquire proceed sale imclone share proceed sale leaseback property net cash inprovide investing activity cash flow financing activity shortterm debt repayment longterm debt borrowing longterm debt repayment interest rate swap termination issuance common stock stock plan excess tax benefit sharebase payment arrangement dividend pay proceed mead johnson initial public offer net cash financing activity effect exchange rate cash cash equivalent decreaseincrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company refer bristolmyer squibb bms company control majorityowned subsidiary intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date february codevelopment cocommercialization license arrangement enter party therapeutic area term include upfront licensing contingent payment arrangement assess determine term economic control entity require consolidation entity entity consolidated control mean majority voting interest refer variable interest entity arrangement material variable interest entity include associated codevelopment cocommercialization license arrangement determine exist reclassification certain prior year amount reclassify conform current year presentation mead johnson nutrition company mead johnson financial result previously report mead johnson segment report discontinued operation year present use estimate preparation financial statement require use management estimate assumption base complex judgment consider reasonable affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine fair value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability stockbase compensation expense pension postretirement benefit include actuarial assumption note pension postretirement postemployment liability fair value financial instrument direct observable market quote inventory obsolescence potential impairment longlive asset allowance bad debt estimate apply revenue recognition policy actual result differ estimate result revenue recognition revenue recognize title substantially risk reward ownership transfer customer generally time shipment case certain sale certain nonus business revenue recognize date receipt purchaser note alliance collaboration discussion revenue recognition relate alliance revenue reduce time recognition reflect expect return estimate base historical experience business trend provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision recognize reduction revenue limit circumstance new product extension exist line product historical experience product similar therapeutic category exist revenue defer right return long exist sufficient historical experience estimate sale return develop sale rebate return accrual sale rebate return accrual establish relate revenue recognize result reduction sale establishment liability accrual recognize base estimate proportion recognize revenue result rebate return prime vendor chargeback accrual cash discount establish similar manner recognize reduction account receivable woman infant child wic rebate relate mead johnson participation competitive bidding process sponsor governmental agency nutritional product table content reduction trade receivables list accrue rebate return liability follow december dollar millions prime vendor chargeback cash discount reduction trade receivables manage healthcare rebate contract discount medicaid rebate sale return adjustment woman infant child wic rebate accrue rebate return income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment cash cash equivalent cash cash equivalent consist treasury security government agency security bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase recognize cost approximate fair value cash cash equivalent maintain foreign currency approximate million december subject currency rate risk marketable security investment company marketable security classify available sale date purchase investment marketable security report fair value december fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity decline fair value consider temporary charge earning consider temporary report component accumulate comprehensive income oci shareholder equity decline fair value determine credit relate charge earning average cost method determine realize gain loss sale available sale security include incomeexpense investment own company ability exercise significant influence maintain account equity method accounting share net income loss equity investment include equity net income affiliate consolidated statement earning equity investment review impairment assess decline market value investment carry value temporary making determination factor evaluate determine loss value recognize include consideration intent ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment impairment loss recognize expense decline market value deem temporary inventory valuation inventory generally state low average cost market table content capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset follow building year machinery equipment fixture year impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow asset dispose report low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software amortization expense million million million million million million include discontinue operation business combination acquire business include consolidated financial statement completion acquisition asset acquire liability assume recognize date acquisition respective fair value excess purchase price estimate fair value net asset acquire recognize goodwill legal cost audit fee business valuation cost business acquisition cost expense incur goodwill acquire inprocess research development intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill impaired carrying reporting unit goodwill exceed estimate fair value biopharmaceutical segment include separate reporting unit base geography annual goodwill impairment assessment complete quarter subsequently monitor potential impairment remain quarter indicate impairment goodwill fair value inprocess research development iprd acquire business combination determine base present value research project project cash flow income approach future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weightedaverage cost capital iprd acquire january initially capitalize consider indefinitelived asset subject annual impairment review occurrence certain event compound reach commercialization asset amortize expect useful life prior january amount allocate acquire iprd expense date acquisition patentstrademark license technology capitalize software amortize straightline basis estimate useful life range year intangible asset deem impair net carry value exceed estimate fair value table content restructure restructuring charge recognize result action streamline operation rationalize manufacture facility significant judgment estimate impact restructuring plan include future termination benefit exit cost incur action place actual result vary estimate product liability accrual product liability include associate legal cost establish undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability recognize undiscounted basis probable recovery realize contingency normal course business loss contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter occur accrual loss contingency recognize probable liability incur loss reasonably estimate gain contingency recognize realize derivative financial instrument derivative financial instrument principally management interest rate foreign currency exposure hold issue trading purpose derivative instrument recognize fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize earning derivative designate cash flow hedge effective portion change fair value derivative report accumulate comprehensive income oci subsequently recognize earning hedge item affect earning cash flow classify consistent underlying hedged item derivative designate assign hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur gain loss immediately recognize designate hedge earning nonderivative instrument designate hedge net investment foreign affiliate nonderivative instrument mainly euro denominate longterm debt effective portion designate nonderivative instrument recognize foreign currency translation section oci ineffective portion recognize earning shipping handle cost shipping handling cost include marketing sell administrative expense million million million million million million include discontinue operation advertising product promotion cost advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci table content research development research development cost expense incur strategic alliance party provide right develop manufacture market andor sell pharmaceutical product right own party certain research development payment alliance partner contingent achievement certain predetermine criterion milestone payment achieve prior regulatory approval product expense research development milestone payment connection regulatory approval capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable research development recognize net reimbursement connection collaboration agreement upfront license milestone payment receive defer amortize estimate life product income recently issue accounting standard october fasb issue asu multipledeliverable revenue arrangement consensus fasb emerge issue task force amendment asc emerge issue task force eitf issue revenue arrangement multiple deliverable standard provide principle allocation consideration multipleelement allow flexibility identify account separate deliverable arrangement eitf introduce estimate selling price method value element bundle arrangement vendorspecific objective evidence party evidence sell price available significantly expand relate disclosure requirement effective prospective basis revenue arrangement enter materially modify fiscal year begin june alternatively adoption retrospective basis early application permit potential impact standard evaluate december fasb issue asu accounting transfer financial asset amendment asc sfa accounting transfer financial asset amendment fasb statement issue june item standard remove concept qualify specialpurpose entity clarifie objective paragraph asc determine transferor entity include transferor financial statement present surrender control transfer financial asset standard effective january expect impact consolidate financial statement december fasb issue asu improvement financial reporting enterprise involve variable interest entity amendment asc sfas amend fasb interpretation issue june standard provide guidance determine enterprise control financial interest variable interest entity determination identify primary beneficiary variable interest entity enterprise power direct activity variable interest entity significantly impact entity economic performance obligation absorb loss right receive benefit entity potentially significant variable interest entity standard require ongoing reassessment enterprise primary beneficiary eliminate quantitative approach previously require determine primary beneficiary new provision standard effective january expect impact consolidate financial statement july fasb issue asc statement financial standard sfas hierarchy generally accept accounting principle standard contain guidance reduce gaap hierarchy level authoritative standard effective september expect impact consolidate financial statement asc fair value measurement disclosure sfas fair value measurement respect nonfinancial asset liability adopt effective january standard define fair value establishe framework measure fair value expand disclosure fair value measurement standard impact consolidate financial statement asc noncontrolle interest consolidate financial statementsan amendment arb sfas noncontrolle interest consolidate financial statementsan amendment arb adopt january result adoption noncontrolle interest balance million previously present million receivables million noncurrent liability present equity december noncontrolle interest present reconcile item consolidate statement earning consolidate statement comprehensive income retain earning consolidate statement cash flow asc sfa business combination business combination january adopt standard require asset acquire liability assume noncontrolle interest acquiree acquisition date table content measure fair value date business combination achieve stage identifiable asset liability include noncontrolle interest acquiree require recognize fair value require fair value iprd recognize indefinitelive intangible asset contingent consideration recognize acquisition date restructuring acquisitionrelate deal cost expense incur addition excess fair value net asset acquire purchase price subsequent change estimate contingency recognize earning note medarex inc acquisition medarex inc medarex purchase accounting detail asc collaborative arrangement eitf issue accounting collaborative arrangement relate development commercialization intellectual property adopt january apply retroactively standard define collaborative arrangement participant actively involve expose significant risk reward depend ultimate commercial success endeavor revenue cost incur party connection collaborative arrangement present gross net base criterion asc overall consideration report revenue gross principal net agent eitf issue report revenue gross principal net agent accounting literature payment collaborator evaluate present base nature arrangement term nature entitys business payment scope accounting literature nature purpose collaborative arrangement disclose accounting policy classification significant financial statement amount relate arrangement activity arrangement conduct separate legal entity account accounting literature require disclosure apply entire collaborative agreement standard impact consolidate financial statement table content note alliance collaboration sanofi company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartanirbesartan hydrochlorothiazide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy plavix clopidogrel bisulfate platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia expiration patent exclusivity right applicable territory company act operating partner own majority control interest territory cover americas australia sanofis ownership interest territory company consolidate country partnership result territory reflect sanofis share result noncontrolle interest company recognize net sale territory comarkete country outside territory germany italy irbesartan spain greece discovery royalty owe sanofi include cost product sell cash flow operating activity partnership territory cover americas australia include operating activity company consolidate statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis recognize operating activity sanofi act operating partner own majority control interest territory cover europe asia company ownership interest territory company consolidate partnership entity territory account equity method reflect share result equity net income affiliate company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia reflect cash provide operating activity company sanofi separate partnership govern copromotion irbesartan alliance company recognize income relate amortization defer income associate sanofis million payment company acquisition interest irbesartan license formation alliance defer income continue amortize expect expiration license income attribute certain supply activity development optout royalty sanofi reflect net income follow summarize financial information reflect consolidated financial statement year end december dollar million territory cover americas australia net sale include comarkete country discovery royalty expense noncontrolle interest net taxis profit distribution sanofi territory cover europe asia equity net income affiliate profit distribution company investment affiliate income irbesartan license fee income supply activity development optout royalty defer income irbesartan license fee table content follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale cost product sell gross profit marketing sell administrative advertising product promotion research development incomeexpense net income current asset current liability cost product sell include discovery royalty million million million pay directly sanofi expense share base applicable ownership percentage current asset current liability include approximately billion billion billion relate receivablespayable attribute respective year net cash distribution company sanofi intercompany balance partnership territory remain current asset current liability consist thirdparty trade receivables inventory amount company sanofi purchase inventory royaltie expense reimbursement otsuka company worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia bipolar mania disorder major depressive disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt term agreement company purchase product otsuka perform finish manufacture sale thirdparty customer company otsuka product currently copromote otsuka united kingdom germany france spain currently germany france spain product invoice thirdparty customer company behalf otsuka company recognize alliance revenue contractual share thirdparty net sale recognize expense related product company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer italy company presently exclusive distributor product company recognize net sale relate cost product sell expense company exclusive right sell abilify country europe americas number countries asia country company recognize net sale relate cost product sell april company otsuka agree extend portion commercialization manufacturing agreement expect loss product exclusivity april term agreement company pay otsuka million amortize reduction net sale extension period unamortized balance include asset begin january share abilify net sale company recognize change follow share net sale period otsuka responsible expense relate commercialization abilify table content begin january expect loss exclusivity april include expect month pediatric extension company receive follow percentage annual net sale share net sale billion billion billion billion billion billion billion billion billion excess billion period otsuka responsible expense relate commercialization abilify addition company otsuka announce enter oncology collaboration sprycel dasatinib ixempra ixabepilone include japan european union market oncology territory begin collaboration fee company pay otsuka annually follow percentage net sale sprycel ixempra oncology territory net sale million million million million million million billion excess billion period otsuka contribute million certain commercial operational expense relate oncology product commercial operational expense relate product territory excess million start otsuka right copromote sprycel company japan market extension oncology collaboration include changeofcontrol provision case acquisition company acquire company compete product abilify new company assume abilify agreement amend oncology collaboration exist today acquire company product compete abilify otsuka elect request acquire company choose div abilify compete product scenario abilify divest otsuka obligate acquire company right abilify agreement amend agreement provide event generic competitor abilify january company option terminate abilify april amendment agreement previously amend remain force company exercise option company receive payment otsuka accord predetermine schedule oncology collaboration terminate time oncology collaboration continue truncated period accord predetermine schedule entire agreement remain unchanged expire june country company exclusive right sell abilify agreement expire later anniversary commercial sale country expiration applicable patent country addition million extension payment total milestone payment otsuka agreement december million million expensed iprd remain million capitalize intangible asset amortize cost product sell remain life agreement follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million net sale amortization extension payment amortization milestone payment unamortize extension payment unamortized milestone payment table content january company grant otsuka exclusive right japan develop commercialize onglyza company expect receive milestone payment base certain regulatory event salesbase payment follow regulatory approval onglyza japan retain right copromote onglyza otsuka japan otsuka responsible development cost japan lilly company commercialization agreement eli lilly company lilly lilly november acquisition imclone system incorporate imclone codevelopment promotion erbitux cetuximab expire erbitux september company codevelopment promotion right canada japan erbitux indicate use treatment patient metastatic colorectal cancer use treatment squamous cell carcinoma head neck agreement cover north america lilly receive distribution fee base flat rate net sale north america include cost product sell october company imclone amend codevelopment agreement merck kgaa merck provide cocommercialization erbitux japan right agreement expire lilly ability terminate agreement determine commercially unreasonable lilly continue erbitux receive marketing approval japan july use erbitux treat patient advance recurrent colorectal cancer company receive pretax profit merck sale erbitux japan share equally lilly company share profit commercialization japan include income company amortize million previously capitalize milestone payment account license acquisition remain term agreement amortization classify cost product sell execution initial commercialization agreement company acquire ownership interest imclone approximate time transaction note accounting investment equity method company sell share imclone approximately billion recognize pretax gain million november january company lilly restructure commercialization agreement describe company imclone relate necitumumab imcf novel target cancer therapy currently phase iii development nonsmall cell lung cancer restructure company share cost develop potentially commercialize necitumumab canada japan lilly maintain exclusive right necitumumab market company fund development cost study fund global study company pay million lilly milestone payment approval canada company recognize sale receive profit necitumumab lilly provide selling effort japan company lilly share commercial cost profit evenly agreement relate necitumumab continue patent expiration party agree terminate follow summarize financial information relate alliance reflect consolidated financial statement year end december dollar million net sale distribution fee amortization milestone payment equity net income affiliate japan commercialization fee unamortized milestone payment gilead company gilead sciences inc gilead joint venture develop commercialize atripla efavirenz emtricitabine tenofovir disoproxil fumarate oncedaily single tablet threedrug regimen combine company sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate canada europe gilead recognize atripla revenue canada countries europe consolidate result joint venture operating result company recognize revenue bulk efavirenz component atripla sale product thirdparty customer limit number country company recognize revenue atripla table content agree purchase product gilead distribute thirdparty customer company revenue relate atripla net sale million million million company account participation joint venture equity method accounting recognize share joint venture result equity net income affiliate consolidated statement earning company equity loss joint venture gilead million million astrazeneca company maintain worldwide codevelopment cocommercialization agreement astrazeneca plc astrazeneca worldwide exclude japan codevelopment cocommercialization onglyza saxagliptin dppiv inhibitor saxagliptin agreement second worldwide include japan codevelopment cocommercialization dapagliflozin sodiumglucose cotransporter sglt inhibitor sglt agreement compound study treatment diabete discover company agreement company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis exclude case saxagliptin japan company manufacture product company cocommercialize dapagliflozin japan share profit loss equally agreement company option decline involvement cocommercialization give country instead receive royalty royalty percentage rate company optsout cocommercialization agreement tiere base net sale july fda approve onglyza adjunct diet exercise improve blood sugar glycemic control adult treatment type diabete mellitus august company astrazeneca launch onglyza october onglyza receive marketing authorization use treat adult type diabetes combination metformin sulfonylurea thiazolidinedione agent diet exercise provide adequate glycemic control company receive astrazeneca total million upfront licensing milestone payment relate saxagliptin agreement million upfront licensing payment relate sglt agreement december include million receive payment defer amortize useful life product income amortization million million million unamortized upfront licensing milestone payment million million december respectively additional milestone payment expect receive company successful achievement development regulatory event salesbase milestone saxagliptin agreement company receive additional million remain development regulatory milestone saxagliptin meet additional million salesbased milestone saxagliptin meet sglt agreement company receive additional million development regulatory milestone dapagliflozin meet additional million salesbased milestone dapagliflozin meet agreement company astrazeneca share development commercialization cost majority development cost initial development plan pay astrazeneca astrazeneca bear cost initial agree development plan dapagliflozin japan additional development cost generally share equally net reimbursement company development cost relate saxagliptin dapagliflozin net research development million million million pfizer company pfizer inc pfizer maintain worldwide codevelopment cocommercialization agreement apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition company receive million upfront licensing payment addition company receive million milestone payment april commencement phase iii clinical trial prevention major adverse cardiovascular event acute coronary syndrome company amortize income million million million upfront licensing milestone payment unamortize upfront license milestone payment million million december respectively pfizer fund development cost initial development plan effective january go forward company fund net reimbursement company apixaban development cost net research development million million million company receive additional payment pfizer additional million base achieve development regulatory milestone company jointly develop clinical marketing strategy share commercialization expense profit loss equally global basis manufacture product arrangement table content exelixis december company exelixis inc exelixis enter global codevelopment cocommercialization arrangement metvegret inhibitor oral anticancer compound license utility ras raf mutant tumor development exelixis term arrangement company pay exelixis million execution agreement pay additional million expensed research development exelixis fund million development exelixis elect continue share development cost exelixis fund future global development cost exclude japan share profit loss equally option copromote fail election exelixis receive milestone royalty net sale royalty percentage rate tiere base net sale company fund development cost japan addition royalty nonus net sale company pay million development regulatory milestone meet compound additional million salesbased milestone meet compound addition company exelixis history collaboration identify develop promote oncology target january company exelixis enter oncology collaboration license agreement exelixis pursue development small molecule ind codevelopment copromotion term agreement company pay exelixis million upfront licensing fee company pay exelixis million ind acceptance milestone exelixis elect fund development cost copromote party equally share development cost profit exelixis optsout codevelopment copromotion agreement company development commercial right successful pay exelixis development regulatory milestone million additional million salesbased milestone royaltie royalty percentage rate tiere base net sale july company hold equity investment exelixis december represent outstanding share zymogenetics january company zymogenetics inc zymogenetic enter global codevelopment arrangement peginterferon lambda novel type interferon treatment hepatitis term arrangement company pay zymogenetic total million upfront licensing milestone payment expense research development zymogenetic fund million global development peginterferon lambda zymogenetics fund development cost europe company fund development cost rest world zymogenetic elect continue share development commercialization cost zymogenetic share profit loss option copromote fail election fund development cost zymogenetic receive royalty net sale royalty percentage rate tiere base net sale company pay zymogenetic royalty nonus net sale addition company pay million hepatitis development regulatory milestone meet million development regulatory milestone potential indication meet additional million salesbased milestone meet alder november company alder biopharmaceuticals inc alder enter global agreement development commercialization ald novel biologic complete phase iia development treatment rheumatoid arthritis term arrangement alder grant company worldwide exclusive right develop commercialize ald potential indication cancer alder retain right grant company option codevelop exclusive right cocommercialize outside united states company pay alder million upfront licensing payment expense research development addition company pay million developmentbase regulatory base milestone payment potential salesbased milestone certain circumstance exceed million royalty net sale royalty percentage rate tiere base net sale company choose option pursue cancer indication company pay additional million developmentbased regulatorybase milestone payment aforementione salesbased milestone royalty net sale royalty percentage rate tiere base net sale table content note business segment information segment information present consistent financial information regularly review chief operating decision maker purpose evaluate performance allocate resource set incentive compensation target planning forecast future period splitoff mead johnson divestiture convatec medical imaging business past year single operating segment remain biopharmaceutical segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization global supply chain organization utilize responsible development delivery product market product distribute sell regional organization serve united states europe middle east africa western hemisphere country emerge market pacific business support global corporate staff function product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross sale large pharmaceutical wholesaler percentage total gross sale follow mckesson corporation cardinal health inc amerisourcebergen corporation select geographic area information follow net sale year end asset dollar millions united states europe middle east africa western hemisphere pacific total net sale key product follow year end december dollar millions plavix avaproavalide reyataz sustiva franchise total revenue baraclude erbitux sprycel ixempra abilify orencia onglyza total capital expenditure depreciation biopharmaceutical segment follow dollar million capital expenditure depreciation table content biopharmaceutical segment result exclude impact significant item indicative current operating performance ongoing result include charge related implementation productivity transformation initiative pti gain loss purchase sale product line business asset upfront license milestone payment segment result exclude earning attribute sanofi noncontrolle interest reconciliation earning continue operation income taxis follow dollar million biopharmaceutical segment result reconcile item downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost process standardization implementation cost gain sale property mature brand product line business litigation charge upfront license milestone payment acquire inprocess research development ar impairment loss sale gain sale imclone share bms foundation funding initiative noncontrolle interest earning continue operation income taxis note restructure productivity transformation initiative design fundamentally change way business run meet challenge change business environment advantage diverse opportunity marketplace transformation nextgeneration biopharmaceutical company continue initiatives pti implement result incurrence approximately billion cost recognition million gain relate sale mature product line business company target create billion annual productivity cost saving cost avoidance approximately expect realize end subsequent pti strategic process design achieve culture continuous improvement enhance efficiency effectiveness competitiveness continue improve cost base implement follow pti charge recognize year end december dollar million provision restructuring accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost total cost gain sale product line business asset net charge accelerate depreciation asset impairment charge shutdown cost include cost product sell primarily relate rationalization manufacturing network biopharmaceutical segment asset continue depreciate facility closure complete remain cost pti primarily attribute process standardization activity recognize incur table content restructuring charge include termination benefit workforce reduction manufacturing sell administrative research development personnel geographic region approximately follow table present detail expense incur connection restructuring activity termination exit termination exit termination exit dollar million benefit cost total benefit cost total benefit cost total charge change estimate provision restructuring follow table represent activity restructuring liability termination exit cost dollar million liability liability total liability january charge change estimate charge discontinue operation spending liability december charge change estimate charge discontinue operation spend convatec divestiture liability december charge change estimate charge discontinue operation spend mead johnson splitoff liability december note medarex inc acquisition september company acquire remain outstanding share medarex own outstanding stock option restrict stock unit completion tender offer expire august september total purchase price billion allocate estimate fair value asset acquire liability assume present acquisition cost million classify incomeexpense medarex biopharmaceutical company focus discovery development commercialization fully human antibodybased therapeutic product address major unmet healthcare need area oncology inflammation autoimmune disorder infectious disease result acquisition right ipilimumab currently phase iii development receive increase biologics development pipeline create balanced portfolio small molecule biologic balanced portfolio associated biopharma model potential optimize exist ipilimumab program drive significant goodwill arise acquisition goodwill iprd intangible asset value acquisition nondeductible tax purpose assign biopharmaceutical segment table content follow purchase price allocation adjust september quarterly report file form reflect final purchase price valuation impact adjustment immaterial prior quarter earning dollar million purchase price cash fair value company equity medarex hold prior acquisition total identifiable net asset cash marketable security current longterm asset inprocess research development intangible asset technology intangible asset license shortterm borrowing current longterm liability defer income taxis total identifiable net asset goodwill income approximately million recognize remeasurement fair value equity interest medarex hold acquisition date include ownership interest genmab million ownership celldex therapeutic inc million subsequently sell december loss million include approximately billion related ipilimumab amortize year amortize year result medarex operation include accompany consolidated financial statement august pro forma supplemental financial information provide impact acquisition material operating result note mead johnson nutrition company initial public offering february mead johnson complete initial public offering ipo sell million share class common stock share net proceed million deduct million underwriting discount commission offer expense allocate noncontrolle interest capital excess par value stock completion ipo million share mead johnson class common stock million share mead johnson class common stock hold company represent interest mead johnson combine voting power outstanding common stock right holder share class common stock class common stock identical regard voting conversion share class common stock entitle vote share share class common stock entitle vote share convertible time election holder share class common stock class common stock automatically convert share class common stock agreement relate separation mead johnson enter include separation agreement transitional service agreement tax matter agreement registration right agreement employee matter agreement note discontinued operation mead johnson nutrition company splitoff splitoff remain interest mead johnson complete december splitoff effect exchange offer previously hold million share mead johnson converting class common stock class common stock million outstanding share company stock result pretax gain approximately billion billion net taxis table content share receive connection exchange value closing price december reflect treasury stock gain exchange determine sum fair value share receive plus net deficit mead johnson attributable company taxis direct expense relate transaction include tax reserve million establish convatec disposition august divestiture convatec business cidron healthcare limited affiliate nordic capital fund vii avista capital partner avista complete gross purchase price approximately billion result pretax gain billion billion net taxis medical imaging disposition january divestiture bristolmyers squibb medical imaging medical imaging avista complete gross purchase price approximately million result pretax gain million aftertax loss million transitional relationship discontinue operation subsequent respective disposition cash flow income associate mead johnson convatec medical imaging business continued generate relate activity transitional nature generally result agreement intend facilitate orderly transfer business operation agreement include service accounting customer service distribution manufacturing generally expire later month date divestiture income generate transitional activity include incomeexpense expect material future result operation cash flow activity relate convatec medical imaging business substantially complete december follow summarize financial information relate mead johnson convatec medical imaging business segregate continue operation report discontinue operation date disposition year end december dollar million net sale mead johnson convatec medical imaging net sale earning income taxis mead johnson convatec medical imaging earning income taxis provision income taxis earning net taxis gain disposal mead johnson convatec medical imaging gain disposal provision income taxis gain disposal net taxis net earning discontinue operation net earning discontinue operation attributable noncontrolle interest net earning discontinue operation attributable bristolmyer squibb company table content note earning share computation basic diluted earning common share ep follow year end december amount million share datum basic eps calculation net earning continue operation attributable bms dividend undistribute earning attributable unvested share net earning continue operation attributable bms basic eps calculation net earning discontinue operation attributable bms basic eps calculation net earning attributable bms basic eps calculation basic eps attributable bms average common share outstanding basic continue operation discontinue operation net earning dilute eps calculation net earning continue operation attributable bms contingently convertible debt interest expense dividend undistribute earning attributable unvested share net earning continue operation attributable bms diluted eps calculation net earning discontinue operation attributable bms diluted eps calculation net earning attributable bms diluted eps calculation dilute eps attributable bms average common share outstanding basic contingently convertible debt common stock equivalent incremental share outstanding assume exerciseveste sharebased compensation average common share outstanding diluted continue operation discontinue operation net earning net earning discontinue operation eps calculation net earning discontinue operation attributable bms dividend undistribute earning attributable unvested share net earning discontinue operation attributable bms ep calculation antidilutive weightedaverage equivalent share stock incentive plans convertible debt total antidilutive share note incomeexpense incomeexpense include year end december dollar million interest expense interest income gain debt buyback termination interest rate swap agreement auction rate security ar impairment foreign exchange transaction lossesgain gain sale product line business asset medarex acquisition net royalty income amortization upfront licensing milestone payment receive alliance partner pension settlementscurtailment incomeexpense table content note income taxis component earning continue operation income taxis categorize base location tax authority follow year end december dollar million nonus total provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective tax rate statutory federal income tax rate earning income taxis dollar million earning continue operation income tax statutory rate foreign tax effect certain operation ireland puerto rico switzerland state local taxis net valuation allowance federal state foreign contingent tax matter acquire inprocess research development expense federal research development tax credit impairment financial instrument foreign decrease effective tax rate primarily unfavorable tax impact relate iprd ar impairment charge less extent high benefit relate certain contingent matter increase effective tax rate primarily high pretax income include gain sale imclone share earning mix high tax jurisdiction partially offset factor low nondeductible charge iprd low ar impairment charge little tax benefit tax rate favorably impact benefit million tax relate final settlement audit internal revenue service tax rate unfavorably impact impairment investment certain ar little tax benefit nondeductible writeoff iprd relate acquisition adnexus therapeutics inc adnexus partially offset tax benefit million quarter favorable resolution certain tax matter internal revenue service relate deductibility litigation settlement expense foreign tax credit claim table content defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions acquire intangible asset intercompany profit inventory item federal foreign tax credit carryforward defer income federal research development tax credit carryforward federal net operating loss carryforward state net operating loss credit carryforward foreign net operating loss carryforward foreign defer tax asset pension postretirement benefit depreciation sharebase compensation repatriation foreign earning legal settlement tax deductible goodwill milestone payment license fee valuation allowance defer tax asset recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable liability noncurrent total valuation allowance defer tax asset establish likely defer tax asset realize december valuation allowance million establish follow item million foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million relate impaired financial instrument net operating loss carryforward acquire result acquisition medarex kosan biosciences inc kosan adnexus subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign tax credit research development tax credit carryforward expire vary amount begin realization foreign tax credit research development tax credit carryforward dependent generating sufficient domesticsource taxable income prior expiration realization assure management believe likely defer tax asset realize income tax payment million million million income tax payment net million cash refund relate foreign tax credit carryback claim current tax benefit realize exercise stock option credit capital excess par value stock million december taxis provide approximately billion undistributed earning foreign subsidiary undistribute earning invest expect permanently invest offshore future earning repatriate earning determine remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide president obamas administration propose reform international tax law adopt increase taxis reduce result operation cash flow business conduct country world subject tax numerous jurisdiction result significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year table content resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation uncertain income tax position standard adopt january result recognition million previously unrecognized tax benefit account increase opening balance retain earning standard require follow expand disclosure end annual reporting period include tabular reconciliation unrecognized tax benefit certain information interest penalty amount reflect uncertain tax position unrecognize income tax benefit unrecognized include income tax interest unrecognize benefit penalty federal state include defer net defer foreign interest income tax income dollar million tax benefit interest penalty penalty benefit tax benefit total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december uncertain tax benefit december reduce deferred tax asset extent uncertainty directly relate asset recognize current noncurrent income taxis payable table content balance unrecognized tax benefit include million uncertain tax position january million december ultimate deductibility highly certain uncertainty time deductibility impact defer tax accounting interest penaltie applicable disallowance short deductibility period affect annual effective tax rate accelerate payment cash tax authority utilization tax attribute early period unrecognized tax benefit recognize impact effective tax rate million january million december gross addition tax position relate current year include million tax reserve relate transfer international unit mead johnson prior ipo splitoff transaction recognize discontinued operation gross reduction tax position relate prior year include million liability relate mead johnson interest penalty relate unrecognized tax benefit classify income tax expense company currently examination number tax authority include major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense company estimate reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit primarily settlement related involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit company anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase reasonably time company believe adequately provide open tax year tax jurisdiction income tax return file federal jurisdiction state foreign jurisdiction exception company subject federal state local nonus income tax examination tax authority follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico january irs announce proposal effective require company disclose uncertain tax provision annual income tax return filing propose requirement apply certain business taxpayer financial statement prepare schedule form include applicable tax return annually result splitoff mead johnson file company consolidated income tax return state combine tax return splitoff date company enter tax sharing agreement mead johnson payment tax sharing agreement represent mead johnson share tax liability reimbursement utilization certain tax attribute company agree indemnify mead johnson outstanding tax liability audit exposure income sale use property taxis exist period prior ipo table content note fair value measurement fair value financial asset liability classify follow category level quote price unadjuste active market accessible measurement date identical asset liability fair value hierarchy give high priority level input level observable price base input quote active market corroborate market datum level unobservable input little market datum available fair value hierarchy give low priority level input december december dollar million level level level total level level level total available sale government agency security equity security prime money market fund corporate debt security commercial paper fdic insure debt security treasury money market fund government agency money market fund float rate security frs auction rate security total available sale asset derivative interest rate swap derivative foreign currency forward derivative total derivative asset total asset fair value derivative foreign currency forward derivative interest rate swap derivative natural gas contract total derivative liability total liability fair value majority ar rate standard poor primarily represent interest insurance securitization valuation model utilize rely exclusively level input lack observable market quote ars portfolio input base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity fair value ar determine internally develop valuation base indicative bid receive underlying asset security evidence fair value investment expect sell recovery amortize cost basis decline fair value consider otherthantemporary table content frs longterm debt security coupon reset periodically benchmark interest rate million principal par frs receive know report default frs underlie asset frs primarily consist consumer loan auto loan collateralize loan obligation monoline security assetbacke security corporate bond loan current lack active market frs general lack transparency underlie asset qualitative analysis rely value frs include discussion broker fund manager default risk underlie security overall capital market liquidity level input decline fair value report temporary loss comprehensive income intention sell investment likely investment require sell recovery amortize cost basis financial asset liability utilize level level input direct indirect observable price quote utilize include libor euribor yield curves foreign exchange forward price nymex future price common stock price quote summary valuation technique level level financial asset liabilitie government agency securitie government agency money market fund value quote market price observable pricing source report date equity security value quote stock price new york stock exchange national association security dealer automate quotation system report date prime money market fund net asset value share corporate debt security commercial paper value quote market price observable pricing source report date fdic insure debt security value quote market price observable pricing source report date treasury money market fund value quote market price observable pricing source report date foreign currency forward derivative asset liability value quote forward foreign exchange price report date counterpartie contract highlyrate financial institution experience significant downgrade valuation fluctuate considerably periodtoperiod volatility underlie foreign currency shortterm maturitie foreign currency forward derivative month counterparty credit risk significant interest rate swap derivative asset liability value libor euribor yield curve credit valuation adjustment report date counterpartie contract highlyrate financial institution experience significant downgrade valuation fluctuate considerably periodtoperiod volatility underlie interest rate drive market condition duration swap addition credit valuation adjustment volatility significant impact valuation interest rate swap change counterparty credit rating credit default swap spread table content note cash cash equivalent marketable security cash cash equivalent million december million december consist prime money market fund government agency security treasury security cash equivalent primarily consist highly liquid investment original maturity month time purchase recognize cost approximate fair value follow table summarize current noncurrent marketable security account available sale debt security equity security december december unrealize unrealized lossgain lossgain carry accumulate carry accumulate dollar million cost fair value value oci cost fair value value oci current marketable security certificate deposit commercial paper government agency securitie treasury bill float rate security total current noncurrent marketable security corporate debt security fdic insured debt security government agency security auction rate security float rate security total noncurrent asset equity security frs unrealized loss position month december follow table summarize activity financial asset utilize level fair value measurement current noncurrent current noncurrent dollar million frs frs ar total frs frs ar total fair value january sale settlement transfer current noncurrent realize loss unrealize gainslosse fair value december contractual maturity available sale debt security december follow dollar million year year year year total available sale certificate deposit commercial paper government agency security corporate debt security fdic insured debt security float rate security auction rate security total available sale table content note receivables receivable include december dollar million trade receivable allowance net trade receivables alliance partner receivables income tax refund claim miscellaneous receivables receivables receivables net deferred income relate alliance partner recognition income result alliance partner receivables defer income reduce million million december respectively additional information alliance partner note alliance collaboration nonus receivables sell nonrecourse basis million million respectively aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively note inventory inventory include december dollar million finish good work process raw packaging material inventory inventory expect remain onhand year million million december respectively include noncurrent asset amount include capitalize cost relate production product program phase iii development subject final food drug administration approval million million december respectively probability future sale status regulatory approval process consider assess recoverability cost note property plant equipment property plant equipment include december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million million million million include discontinue operation capitalize interest million million million table content note goodwill intangible asset change carry goodwill segment follow dollar million biopharmaceutical total balance january kosan acquisition adnexus purchase price allocation adjustment sale medical imaging sale convatec sale mature brand business egypt balance december medarex acquisition mead johnson splitoff balance december intangible asset include december december gross net gross net estimate carry accumulate carrying carry accumulate carry dollar million useful life amortization amortization patentstrademark year license year technology year capitalize software year inprocess research development note total intangible asset change intangible asset follow dollar million intangible asset carry january capitalize software addition medarex acquisition adnexus acquisition mead johnson splitoff sale convatec medical imaging asset hold sale amortization impairment charge intangible asset carry december amortization expense include discontinue operation million million million expect future amortization expense december finitelive intangible asset million million million million million million note accrue expense accrue expense include december dollar million employee compensation benefit royaltie accrue research development restructuringcurrent pension postretirement benefit accrue litigation total accrue expense table content note equity change common share treasury stock capital excess par value stock follow cost capital excess common share treasury treasury par value dollar share million issue stock stock stock balance january employee stock compensation plan balance december employee stock compensation plan balance december mead johnson ipo adjustment mead johnson net asset transfer mead johnson splitoff employee stock compensation plan balance december accumulate balance relate component comprehensive incomeloss oci net taxis follow pension accumulate foreign derivative currency qualify postretirement available comprehensive dollar million translation effective hedge benefit sale security incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss balance december comprehensive incomeloss balance december reconciliation noncontrolle interest follow dollar millions balance january mead johnson ipo adjustment mead johnson net asset transfer mead johnson splitoff net earning attributable noncontrolle interest comprehensive income attributable noncontrolle interest distribution balance december noncontrolle interest primarily relate partnership sanofi territory cover america net sale plavix net earning attributable noncontrolle interest present net taxis million million million consolidated statement earning correspond increase provision income taxis distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis include operating activity consolidate statement cash flow activity include pretax income distribution relate partnership net earning noncontrolle interest include discontinue operation million million treasury stock recognize cost reacquire share treasury share acquire mead johnson splitoff recognize fair value stock splitoff date share issue treasury recognize utilize firstin firstout method table content note pension postretirement postemployment liability company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal pension plan bristolmyers squibb retirement income plan represent approximately consolidate pension plan asset obligation fund policy contribute amount provide current service fund past service liability plan benefit base primarily participant year credit service compensation plan asset consist principally equity fixedincome securities comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost define benefit pension postretirement benefit plan include pension benefit benefit dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization net actuarial loss net periodic benefit cost curtailment settlement special termination benefit total net periodic benefit cost continue operation discontinue operation total net periodic benefit cost retirement income plan plan amend june amendment eliminate credit future benefit relate service effective december salary increase continue consider additional fiveyear period determine benefit obligation relate prior service plan amendment account curtailment result applicable plan asset obligation remeasure remeasurement result million reduction accumulate oci million net taxis correspond decrease unfunded status plan curtailment update plan asset valuation change discount rate curtailment charge million recognize incomeexpense second quarter remain unrecognize prior service cost addition participant reclassify inactive benefit plan purpose actuarial gain loss amortize expect weightedaverage remain life plan participant year connection plan amendment contribution principal define contribution plan puerto rico expect increase effective january net impact action expect reduce future retiree benefit cost future cost continue subject market condition factor include actual expect plan asset performance interest rate fluctuation lumpsum benefit payment retirement income plan plan remeasure transfer certain plan asset relate obligation new mead johnson plan active mead johnson participant february remeasurement result million reduction accumulate oci million net taxis quarter correspond decrease unfunded status plan update plan asset valuation change discount rate net actuarial loss prior service cost expect amortize accumulate oci net periodic benefit cost dollar million pension benefit benefit amortization net actuarial loss amortization prior service costbenefit table content change define benefit postretirement benefit plan obligation asset fund status amount recognize consolidated balance sheet follow pension benefit benefit dollar million benefit obligation begin year service costbenefit earn year interest cost plan participant contribution curtailment settlement actuarial lossesgain transfer mead johnson retiree drug subsidy benefit pay special termination benefit exchange rate lossesgain benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement transfer mead johnson retiree drug subsidy benefit pay exchange rate lossesgain fair value plan asset end year fund status assetsliabilitie recognize asset accrue expense pension postretirement liability accrue benefit cost fund status recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service costbenefit total table include activity relate mead johnson pension postretirement plan separation activity certain define benefit pension postretirement plan asset liability transfer mead johnson define benefit pension postretirement plan relate plan asset liability transfer participant allocate base assumption set forth employee matter agreement reduction accumulate postretirement benefit obligation impact medicare prescription drug improvement modernization act million million million accumulate benefit obligation define benefit pension plan million million december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset table content actuarial assumption weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citigroup pension discount curve develop discount rate plan factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year expect return plan asset determine expect rate return calculate value asset refer marketrelated value marketrelate value exceed fair value plan asset million billion december respectively change primarily drive asset gain offset additional recognition significant loss incur plan asset difference assume actual return amortize marketrelated value straightline basis threeyear period gain loss result change actuarial assumption change discount rate difference assume actual experience difference actual assume return plan asset gain loss difference amortize market relate value amortize extent exceed high marketrelated value project benefit obligation respective plan result approximately million related pension benefit expect amortized majority remain actuarial loss amortize life expectancy plan participant plan expect remain service period plan assume healthcare cost trend rate december follow healthcare cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume healthcare cost trend rate effect amount report healthcare plan onepercentagepoint change assume healthcare cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation table content plan asset fair value pension postretirement plan asset asset category december follow dollar million level level level total equity security fix income security treasury bill government agency security government back index link government security corporate debt shortterm investment mortgage asset back security hedge fund real estate venture capital limited partnership insurance contract cash cash equivalent total plan asset fair value equity security security classify level include publicly trade equity trade national security exchange value report sale price reporting date sale day report bid price publicly trade equity trade overthecounter market value report bid price reporting date security classify level value offer trade broker dealer value net asset value share hold year end base fair value underlie investment level equity security value estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value fix income security security classify level value quote market price observable pricing source report date security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating treasury bill security classify level value quote market price observable pricing source report date government agency security security classify level value quote market price observable pricing source report date government back index link government security security classify level value quote market price broker dealer quotation transparent pricing source report date corporate debt security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating security classify level value estimate bid broker thirdparty vendor source utilize expect cash flow stream datum include counterparty credit quality default risk discount rate overall capital market liquidity shortterm investment security classify level value net asset value share hold year end base fair value underlie investment mortgage asset back security security classify level value quote market price observable pricing source report date value base comparable security similar yield credit rating purpose underlie loan security classify level value estimate bid broker thirdparty vendor source utilize expect cash flow stream uncorroborated datum include counterparty credit quality default risk discount rate overall capital market liquidity hedge fund security classify level value net asset value share hold year end base fair value underlie investment table content real estate interest classify level value quote market price observable pricing source report date value base comparable investment interest classify level carry estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value venture capital limit partnership interest classify level carry estimate fair value estimate fair value base fair value underlie investment value cost plus minus accumulate earning loss approximate fair value insurance contract interest classify level carry contract value approximate estimate fair value estimate fair value base fair value underlie investment insurance company insurance contract hold certain nonus pension plan cash cash equivalent security classify level highly liquid investment original maturity month time purchase recognize cost approximate fair value follow summarize activity financial asset utilize level fair value measurement mortgage venture asset capital equity corporate back real limited insurance dollar million security debt security estate partnership contract total fair value january purchase sale issuance settlement net realize lossesgain unrealized gainslosse fair value december investment strategy emphasize equity order achieve higher expect return low expense require cash contribution longterm target asset allocation public equity international private equity fix income maintain pension plan cash contribution benefit payment rebalance target necessary investment diversify major asset category approximately pension plan equity investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative private equity typically value month lag bristolmyers squibb company common stock represent plan asset december contribution contribution pension plan million include million mead johnson million million contribution pension plan expect approximate million million contribute january contribution international pension plan million million million contribution international plan expect range million million estimate future benefit payment benefit pension medicare dollar millions benefit gross subsidy net year table content saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match contribution plan million million million discuss retirement income plan plan amend certain enhancement define contribution plan allow increase match additional contribution contribution define contribution plan expect approximately million post employment benefit plan longterm disability benefit offer certain employee post employment liability million million december respectively expense relate benefit million million million termination indemnity plan company certain statutory termination obligation europe obligation recognize undiscounted basis assume employee termination measurement date liability recognize obligation million december million december million december vested benefit obligation recognize assume employee separation measurement date note employee stock benefit plan employee stock plan shareholder approve stock award incentive plan plan plan replace stock incentive plan plan expire plan provide million new share common stock reserve delivery participant plus share remain available new grant plan share recapture outstanding award plan share actually deliver participant connection award restriction lapse reduce number share reserve share tender prior year pay purchase price option share previously utilize satisfy withholding tax obligation exercise continue available reserve share common stock reserve issuance pursuant stock plan option conversion prefer stock million million december respectively share available grant active plan million million december respectively adjust combination plan plan plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year generally share stock option exercise issue treasury stock additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price stock appreciation right thousand outstanding account liability award december plan plan provide grant common stock key employee subject restriction continuous employment restriction generally expire year period date grant compensation expense recognize restrict period restrict stock unit grant instead restrict stock stock unit right receive stock end specify vest period voting right plan plan incorporate longterm performance award award year cycle deliver form target number performance share unit number share ultimately issue calculate base actual performance compare earning target performance criterion establish begin performance period award annual goal maximum payout threshold target meet performance period payment plan annual period table content stockbase compensation expense follow year end december dollar million stock option restrict stock longterm performance awards total stockbase compensation expense continue operation discontinue operation total stockbase compensation expense defer tax benefit relate stockbase compensation expense alternative method determine pool excess tax benefit elect stock option stock option activity follow share common stock issue weightedaverage share million plan exercise price share balance january grant exercise expire forfeit balance december grant exercise expire forfeit balance december grant exercise expire forfeit balance december december unrecognized compensation cost relate stock option million expect recognize weightedaverage period year additional information relate stock option grant exercise plan plan summarize follow year end december amount million share datum stock option grant weightedaverage grant date fair value share total intrinsic value stock option exercise cash proceed exercise stock option follow table summarize information concern stock compensation plan currently outstanding exercisable option number security issue weightedaverage exercise exercise outstanding option price outstanding share million right option right plan category equity compensation plan approve shareholder equity compensation plan approve shareholder plan terminate share long issue table content follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted weight average weighted average weight remain average aggregate remain average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price value number life price value range exercise price outstanding year share million exercisable year share million vest expect vest aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december receive option holder option holder exercise option date million inthemoney option exercisable december million outstanding option exercisable weightedaverage exercise price december fair value stock option estimate grant date blackschole option pricing model stock option service condition monte carlo simulation model option service market condition follow weightedaverage assumption valuation expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs expect volatility assumption require blackschole model derive calculate year historical volatility weighting equally derive imply volatility blend historical imply volatility approach expect volatility believe representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect grant date dividend yield assumption base historical expect dividend payout expect life stock option represent weightedaverage period stock option remain outstanding derive output latticebinomial model expect life impact underlying assumption calibration model model assume employee exercise behavior function option remain vested life extent option inthemoney model estimate probability exercise function variable base historical exercise cancellation prior option grant stockbased compensation expense base award ultimately expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate adnexus acquire october connection acquisition million share adnexu incentive stock option isos assume replace million share company isos convert option retain original vest schedule include vest commencement date expiration date blackschole model determine expect term individual isos valuation result weightedaverage expect term year weightedaverage fair value october table content restrict stock award restrict stock unit weightedaverage share thousand number share grantdate fair value nonveste share january grant vested forfeited nonveste share december grant vested forfeited nonveste share december grant vested forfeited nonveste share december expect vest december unrecognized compensation cost relate nonveste restrict stock million expect recognize weighted average period year fair value nonveste share restrict stock award unit determine base closing trading price company common stock grant date longterm performance award fair value performance award estimate date grant monte carlo simulation model market condition model utilize multiple input variable determine probability satisfy market condition stipulate grant calculate fair value longterm performance award fair value performance award base closing trading price common stock grant date award contain market condition fair value award grant discount riskfree interest rate date grant participate dividend valuation model performance award follow assumption weightedaverage expect riskfree grant year grant date expect volatility dividend yield interest rate weightedaverage expect volatility base year historical volatility level company common stock expect dividend yield base historical dividend payment riskfree interest rate reflect yield year zero coupon treasury bond base performance share contractual term fair value performance award amortize performance period award performance share unit grant million million assume payout share unit outstanding million million december respectively thousand share issue december unrecognized compensation cost relate performance share unit plan million expect recognize weightedaverage period year table content note shortterm borrowing longterm debt shortterm borrowing include december dollar millions bank draft principal value yen note convertible senior debenture demand note payable mead johnson repay january total medarex acquisition medarexs outstanding convertible senior note assume note adjust right receive cash time principal outstanding equivalent share time prior maturity longterm debt include december dollar million principal value note note euro note euro note note note debenture debenture debenture float rate convertible senior debenture industrial revenue bond yen note variable rate industrial revenue bond subtotal adjustment principal value fair value interest rate swap unamortize basis adjustment swap termination unamortized bond discount total portion float rate convertible senior debenture redeem holder par september fundamental change ownership occur debenture callable par time company debenture conversion price equal conversion rate share principal subject certain antidilutive adjustment maximum conversion rate share principal debenture pay interest quarterly annual rate equal month libor reset quarterly minus yield zero february mead johnson company borrower mead johnson guarantor indirect majorityowne subsidiary enter year syndicate revolve credit facility agreement fourth quarter mead johnson borrow million revolve credit facility issue note total billion proceed repay certain intercompany debt prior splitoff table content million notional debt repurchase million notional interest rate swap relate debt repurchase terminate follow table summarize activity include swap basis adjustment principal repurchase loss termination previously earning dollar million price repurchase proceed terminate swap impact principal value debenture debenture note total fixedtofloate interest rate swap execute convert million note note fix rate debt variable rate debt million notional fixedtofloate interest rate swap agreement terminate proceed million basis adjustment debt equal proceed swap termination recognize reduction interest expense remain life underlie debt discussion interest rate swap note financial instrument january fixedtofloate interest rate swap execute convert million debenture million debenture fix rate debt variable rate debt swap qualify fair value hedge debt instrument interest payment include payment interest rate swap million million million cash receipt interest rate swap million million million exclude interest payment principal value longterm debt obligation million december million remain million later fair value longterm debt million million december respectively estimate base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument billion year revolve credit facility syndicate lender mature december maintain facility extendable consent lender contain customary term condition include financial covenant ratio consolidate net debt consolidated capital exceed end quarter company compliance covenant inception facility borrowing outstanding facility december december million financial guarantee provide form standby letter credit performance bond standby letter credit insurance company support thirdparty liability program performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund table content note financial instrument exposure market risk change currency exchange rate interest rate result certain derivative financial instrument available costeffective basis hedge underlie economic exposure primary net foreign currency translation exposure euro japanese yen canadian dollar british pound australian dollar mexican peso chinese renminbi foreign currency forward contract manage exposure instrument generally qualify cash flow hedge accounting treatment manage consolidated basis efficiently net exposure advantage natural offset derivative instrument interest rate risk management strategy derivative instrument principally comprise fixedto float rate interest swap generally qualify fairvalue hedge accounting treatment addition financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose cash flow hedge foreign currency forward contract foreign currency forward contract utilize hedge forecast intercompany transaction certain foreign currency contract designate foreign currency cash flow hedge appropriate notional fair value amount contract million million net liability million million net asset december respectively majority contract qualify hedge probable forecast cash flow effective portion change fair value temporarily report accumulate oci recognize earning hedge item affect earning follow table summarize outstanding foreign currency forward contract december fair value contract base yearend currency rate view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weightedaverage notional fair value dollar million currency rate strike price assetliability maturity foreign currency forward cash flow hedge australian dollar australian dollar brazilian real british pound british pound canadian dollar canadian dollar euro euro japanese yen japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedge defer loss foreign currency forward contract qualify cash flow hedge accounting million million net taxis december expect reclassify earning month effectiveness assess inception hedge quarterly basis assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion change fair value include current period earning impact hedge ineffectiveness earning significant cash flow hedge accounting discontinue forecast transaction long probable occur originally forecast date day hedge long effective discontinued foreign exchange hedge result pretax loss million report incomeexpense table content nonqualifye foreign currency forward contract foreign currency forward contract utilize hedge foreign currencydenominate monetary asset liability primary objective contract protect dollar value foreign currencydenominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar contract designate hedge adjust fair value incomeexpense occur substantially offset change fair value underlie foreign currency denominate monetary asset liability notional fair value amount contract significant december furthermore foreign currency forward contract offset exposure certain asset liability earning denominate certain foreign currency contract designate hedge change fair value recognize incomeexpense occur contract nature hold december quarter foreign currency forward contract hedge anticipate earning denominate australian canadian dollar contract designate qualifying hedge gain loss derivative recognize incomeexpense occur hedge net investment nonus dollar borrowing primarily million note million note billion total hedge foreign currency exposure net investment certain foreign affiliate borrowing designate hedge net investment effective portion foreign exchange gain loss recognize foreign currency translation cta component accumulate oci include million relate translation note december ineffective portion note recognize million loss million gain fair value hedge interest rate contract derivative instrument interest rate risk management strategy principally fixedtofloate interest rate swap designate fairvalue hedge total notional amount fair value outstanding interest rate swap billion million net asset billion million net asset december respectively swap underlie debt benchmark risk hedge recognize fair value swap intend create appropriate balance fix float rate debt basis adjustment debt qualify fair value hedge relationship amortize earning adjustment interest expense remain life debt underlie swap terminate prior maturity terminate swap qualify cash flow hedge recognize accumulate oci amortize earning remain life debt hedge debt remain outstanding table content follow summarize earning impact terminate interest rate swap pretax income unrecognized gainslosse expense recognize year longterm comprehensive interest rate swap termination debt loss dollar million interest rate swap lock associate note swap associate debenture debenture note note note note note debenture debenture debenture note total interest rate swap follow summarize interest rate swap outstanding december notional underlie variable rate year fair debt receive transaction maturity value dollar million swap associate note month libor note month libor note month libor million note month eur euribor million note month eur euribor debenture month libor note month libor note month libor note month libor total interest rate swap impact earning interest rate swap qualify fair value hedge follow dollar million recognize interest expense amortization basis adjustment swap termination recognize interest expense gain swap termination recognize incomeexpense total follow summarize fair value outstanding derivative balance sheet balance sheet location location dollar million derivative designate hedge instrument interest rate contract asset accrue expense foreign currency forward contract asset accrue expense hedge net investment longterm debt natural gas contract accrue expense subtotal derivative designate hedge instrument foreign currency forward contract asset accrue expense total derivative table content impact oci earning foreign currency forward contract natural gas contract forward start swap qualified cash flow hedge follow foreign currency forward natural gas forward start contract contract swap total impact dollar million net carrying january cash flow hedge defer oci cash flow hedge reclassify cost product soldinter expense effective portion change defer taxis cash flow hedge reclassify net earning business divestiture net carrying december impact oci earning nonderivative debt designate hedge net investment follow net investment hedge dollar million net carrying january change spot value nonderivative debt designate hedge defer ctaoci net carrying december impact earning nonqualifying derivative recognize incomeexpense year end december significant derivative financial instrument present certain market counterparty risk concentration counterparty risk mitigate bank worldwide standard poor moodys longterm debt rating high addition conventional derivative financial instrument utilize consolidated financial statement materially impact counterpartie fail perform accord term agreement currently collateral form securitization require furnish counterpartie derivative financial instrument discussion fair value financial instrument note fair value measurement note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease expense million million million net sublease income million million million million million million include discontinue operation sale leaseback administrative facility paris france complete million million result pretax gain million gain defer reduce future lease cost lease period year table content note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise time time ordinary course business relate product liability patent commercial consumer environmental security matter company recognize accrual contingency probable liability incur loss reasonably estimate significant litigation charge million million million net revise estimate previously accrue amount cash payment relate significant litigation million million million significant matter describe company believe substantial defense matter company future incur judgment enter settlement material adverse effect result operation particular period intellectual property plavix litigation plavix currently company large product rank net sale plavix patent subject number challenge include litigation apotex inc apotex corp apotex describe significant market product reasonably possible estimate impact lawsuit company loss market exclusivity plavix sustain generic competition material company net sale plavix result operation cash flow material company financial condition liquidity company product partner sanofi company intend vigorously pursue enforcement patent right plavix plavix litigation patent infringement litigation apotex relate matter previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute united states district court southern district new york district court entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership apotex suit base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix previously report district court uphold validity enforceability patent maintain main patent protection plavix november district court rule apotexs generic clopidogrel bisulfate product infringe patent permanently enjoin apotex engage activity infringe patent include market generic product patent expire apotex appeal district court decision december united states court appeal federal circuit circuit court affirm district court rule sustain validity patent apotex file petition circuit court rehear banc march circuit court deny apotexs petition case remand district court proceeding relate damage july apotex file petition writ certiorari supreme court request supreme court review circuit court decision november supreme court deny petition decline review circuit court decision december company file motion district court summary judgment damage january apotex file motion seek stay ongoing damage proceeding pende outcome reexamination plavix patent patent trademark office pto describe motion pende previously disclose company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit reddys laboratories inc reddys laboratories ltd reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt watson pharmaceuticals inc watson laboratories inc watson sun pharmaceuticals sun lawsuit reddys teva cobalt relate patent reddys sign consent judgment favor sanofi bms concede validity infringement patent previously report patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex consequently july district court enter judgment cobalt teva permanently enjoin cobalt teva engage activity infringe patent patent expire cobalt teva file appeal july circuit court issue mandate teva appeal bind teva decision apotex litigation august cobalt consent entry judgment appeal agree bind circuit court decision apotex litigation lawsuit watson file october base patent patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix december table content court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter bms watson enter stipulation dismiss case april pharmastar file request inter part reexamination patent pto pto grant request july july pto vacate reexamination proceeding lawsuit sun file july base infringement patent patent respect patent sun agree bind outcome apotex litigation reddys teva cobalt watson sun file anda fda respect reddys teva cobalt watson exclusivity period statutory stay periods hatchwaxman act expire accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage june apotex file request parte reexamination patent pto august pto agree reexamine patent december pto issue nonfinal office action reject claim cover plavix include claim previously uphold litigation apotex refer sanofi intend respond office action february possible time reasonably assess outcome reexamination patent pto plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity additionally possible time reasonably assess damage recover company apotexs ability pay damage event company prevail patent litigation additionally november apotex file lawsuit new jersey superior court entitle apotex inc sanofiaventis seek payment million plus interest relate breakup propose settlement agreement plavix litigation international plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex change apotex august apotex file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september australian court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid view decision possible generic company develop seek registration australia alternate salt form clopidogrel bisulfate hydrochloride hydrobromide taurocholate company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september federal court australia hold claim patent invalid november company sanofi apply high court australia special leave appeal judgment court plavix previously disclose yes pharmaceutical development service gmbh yes pharmaceutical file application marketing authorization germany alternate salt form clopidogrel application rely datum study originally conduct sanofi bms plavix german health authority bfarm grant marketing authorization yes pharmaceutical product datum protection plavix expire july sanofi bms file objection grant marketing authorization ground datum exclusivity right infringe yes pharmaceutical partner seek immediate enforcement marketing authorization deny bfarm yes pharmaceutical partner file legal motion immediate enforcement administrative court grant yes pharmaceutical partner hexal ratiopharm begin continue market product germany sanofi bms appeal decision administrative court appeal reject administrative appeal court party objection bfarm dismiss bfarm sanofi bms appeal decision administrative court cologne matter currently pende table content plavix canada apotex inc april apotex file impeachment action sanofi federal court canada allege sanofis canadian patent patent invalid patent cover clopidogrel bisulfate patent issue prohibition action canada previously disclose canadian federal court ottawa reject apotexs challenge patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex preclude approval apotexs abbreviate new drug submission patent expire decision affirm appeal federal court appeal supreme court canada june sanofi file defense impeachment action file suit apotex infringement patent plavix canada cobalt previously disclose sanofi sanofisynthelabo canada institute prohibition action federal court canada cobalt minister health response noa cobalt direct patent canadian patent patent cobalt noa indicate file ands clopidogrel bisulfate tablet seek notice compliance and expiration patent cobalt allege patent invalid patent invalid infringe follow supreme court canada decision apotex inc sanofisynthelabo canada inc scc dismiss apotexs appeal uphold validity patent describe federal court canada grant sanofis application order prohibition minister health cobalt preclude approval cobalt and patent expire sanofi pursue prohibition action respect patent intellectual property litigation abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceutical sun zydus pharmaceuticals usa inc apotex relate patent cover aripiprazole expire april include additional sixmonth pediatric exclusivity period aripiprazole comarketed company otsuka abilify lawsuit currently pende district court district new jersey month stay hatchwaxman act expire accordingly final approval fda possibly occur early provide generic company authorization distribute generic aripiprazole product subject legal remedy otsuka apply include injunctive relief damage possible time reasonably assess outcome lawsuit impact company generic company launch risk otsuka prevail lawsuit generic competition likely result substantial decrease sale abilify material adverse effect result operation cash flow material financial condition atripla april teva file anda manufacture market generic version atripla teva send gilead paragraph certification letter challenge orange book list patent atripla atripla product joint venture company gilead gilead file patent infringement action teva united states district court southern district new york january company receive notice teva amend anda challenge additional orange book list patent atripla time company patent right cover efavirenz composition matter method use challenge company currently review legal option possible time reasonably assess outcome lawsuit impact company reyataz october teva file anda manufacture market generic version reyataz company receive paragraph certification letter teva challenge orange book list patent reyataz december company novartis pharmaceutical corporation file patent infringement lawsuit district court district delaware teva infringement list patent cover reyataz trigger automatic month stay approval tevas anda possible time reasonably assess outcome lawsuit impact company table content general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth bristolmyers squibb company allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant july judgment favor defendant affirm california court appeals november california supreme court grant plaintiff petition review possible time reasonably assess outcome lawsuit impact company event plaintiff successful appeal rxusa wholesale litigation previously disclose july complaint file drug wholesaler rxusa wholesale inc district court eastern district new york company drug manufacturer drug wholesaler officer defendant mckesson wholesale distribution industry trade group rxusa wholesale inc alcon labs inc complaint allege violation federal new york antitrust law law plaintiff claim defendant allegedly engage anticompetitive act result exclusion plaintiff relevant market seek million damage trebling relief september district court grant company defendant motion dismiss plaintiff appeal district court decision court appeal second circuit antitrust litigation previously disclose lawsuit comprise individual suit purport class action file company district court southern district ohio western division plaintiff include pharmacy chain individually assignee certain wholesaler health welfare benefit plansfund individual resident state lawsuit allege thing purport settlement apotex patent infringement litigation violate sherman act relate law plaintiff seek thing permanent injunctive relief bar apotex settlement andor monetary damage putative class action file behalf direct purchaser consolidate caption plavix direct purchaser antitrust litigation putative class action file behalf indirect purchaser consolidate caption plavix indirect purchaser antitrust litigation amend complaint file october defendant file consolidated motion dismiss december remain pende possible time reasonably assess outcome lawsuit impact company shareholder derivative action previously disclose july certain member board director current officer company name derivative action file new york state supreme court john frank peter dolan donald beebout peter dolan derivative action file federal district court steven sampson james robinson iii complaints allege breach fiduciary duty allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex plaintiff seek monetary damage behalf company contribution indemnification decision file december state court grant motion dismiss complaint frank beebout relate certain member board director later dismiss complaint officer decision date august federal district court grant company motion dismiss sampson action plaintiff appeal district court decision circuit court appeal second circuit december district court grant final approval settlement party material company conclude matter security litigation bristolmyers squibb security litigation previously disclose june july putative class action complaint minneapolis firefighter relief assoc bristolmyers squibb jean lai bristolmyers squibb company file district southern district new york company company chief executive officer peter dolan chief financial officer andrew bonfield complaints allege violation security law allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex september court dismiss lai case prejudice change caption case bristolmyer squibb security litigation appoint ontario teacher pension plan board lead plaintiff october ontario teachers pension plan board file amend complaint make similar allegation early file complaint name additional officer long name andrew bonfield defendant decision date august federal district court deny defendant motion dismiss december district court grant final approval settlement party payment million conclude matter table content pricing sale promotional practice litigation investigation abilify state attorney general investigation march company receive letter delaware attorney general office advise multistate coalition investigate certain abilify marketing practice violate respective state consumer protection statute possible time reasonably assess outcome investigation potential impact company awp litigation previously disclose company number pharmaceutical manufacturer defendant number private class action suit bring attorney general state action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps company remain defendant state attorney general suit pende state court country previously report set class action consolidate district court district massachusetts awp mdl august district court grant preliminary approval propose settlement awp mdl plaintiff claim company million plus half cost class notice maximum payment million final approval hearing currently schedule occur july california litigation previously disclose august county santa clara file purport class action company numerous pharmaceutical manufacturer behalf putative class city county california cover entity purchase drug pursuant drug discount program allege manufacturer provide proper discount cover entity discovery matter ongoing district court northern district california deny plaintiff motion certify class prejudice possible time reasonably assess outcome lawsuit potential impact company omnicare qui tam litigation april company serve qui tam complaint file district court district massachusetts employee omnicare inc omnicare omnicare provider pharmaceutical care senior decline intervene lawsuit complaint allege civil violation federal state false claim act base allegation company pharmaceutical manufacturer pay omnicare kickback switch medication omnicare patient damage government private payer october plaintiff voluntarily dismiss claim company prejudice product liability litigation company party product liability lawsuit previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit claim personal injury allegedly sustain plavix appear united states district court district new jersey district court december company defendant action district court execute tolling agreement respect unfiled claim potential additional plaintiff possible time reasonably assess outcome lawsuit potential impact company hormone replacement therapy company number defendant masstort litigation plaintiff allege thing hormone therapy product include hormone therapy product manufacture company estrace estradiol delestrogen ovcon cause breast cancer stroke blood clot cardiac injury woman defendant aware risk fail warn consumer december company defendant lawsuit file behalf approximately plaintiff federal state court company hormone therapy product sell company january august possible time reasonably assess outcome lawsuit company party impact company table content environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate thirdpartie cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect passaic river remediation natural resource damage claim previously disclose september new jersey department environmental protection njdep issue administrative enforcement directive require company company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river lpr directive name company release nearby bulk chemical reprocess facility operate predecessor mckesson corp subsequently epa issue notice letter numerous party company request performance remedial investigationfeasibility study rif condition lpr consent agreement epa group party commit pay roughly half million estimate rif epa time epa substantially increase estimate scope cost rif result epa agree allow group perform remain rif task group estimate total cost complete rif relate task exceed million group negotiate amend consent agreement epa conduct remain rif work effective process company mckesson buy remain rif task separately company agree pay approximately thousand rif task previously fund mckesson work cooperatively go forward subject later reallocation mid epa announce plan seek implementation earlyaction remedial measure address highly contaminate portion lpr rif complete epa indicate expect select action mid subgroup cooperate private party commence discussion federal natural resource trustee agency concern agreement assess natural resource damage lpr remain party include company mckesson decline discuss proposal scope cost earlyaction seek epa thoroughly understand njdep file suit set party tie facility suspect significant discharge lpr recover cost unspecified damage case languish recently defendant file thirdparty claim member cooperate group numerous party claim seek contribution cost action defendant fund response action relate lpr defendant company claim group member actively discuss strategy coordinate action company participate effort group currently plan add company litigation remains see new defendant extent liability company face relate risk determine new brunswick facility environmental personal injury lawsuit previously disclose lawsuit file company superior court middlesex county behalf current resident new brunswick live adjacent company new brunswick facility complaint allege personal injury property damage result soil groundwater contamination property stem historical operation new brunswick facility october new jersey supreme court grant mass tort status case transfer new jersey superior court atlantic county centralize case management purpose company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company table content north brunswick township board education previously disclose october company contact counsel represent north brunswick board education boe site waste material squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january new jersey department environmental protection njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost company actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter informal mean include mediation bind allocation necessary central component agreement provision company interim funding help defray cleanup cost assure work interrupt company transmit initial interim funding payment december second require payment november party commence mediation late effort successful party bind allocation process addition september township boe file suit party allege contribute waste material site mediation agreement boe township agree forbear assert claim company remains see defendant new suit seek implead company proceeding sec germany investigation previously disclose october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal sec inquiry encompass matter investigation german prosecutor munich germany resolve company understand inquiry concern potential violation foreign corrupt practice act company cooperate sec medarex shareholder litigation july company medarex announce signing merger agreement provide acquisition medarex company tender offer share cash follow announcement certain medarex shareholder file similar lawsuit state federal court relate transaction medarex member medarexs board director company follow consolidation state court action august party enter memorandum understand mou pursuant party reach agreement principle settle state federal action pursuant agreement mou thing medarex certain supplemental disclosure tender offer period party agree present superior court new jersey stipulation settlement documentation require order obtain approval court settlement dismissal action term set forth mou propose settlement remain subject class notice approval court table content note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earningsloss discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earningsloss discontinue operation net earning common share dilute net earning continue operation net earningsloss discontinue operation net earning common share dividend declare common share cash cash equivalent marketable security dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earning discontinue operation net earning common share dilute net earning continue operation net earning discontinue operation net earning common share dividend declare common share cash cash equivalent marketable security earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset table content follow table reconcile previously report datum current year quarterly datum update discontinued operation relate mead johnson note discontinued operation quarter second quarter quarter adjust adjust adjust report report report mead mead mead previously johnson december previously johnson december previously johnson december dollar million share datum report disposition report disposition report disposition net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earningsloss discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earningsloss discontinue operation net earning common share dilute net earning continue operation net earningsloss discontinue operation net earning common share quarter second quarter adjust adjust report report mead mead previously johnson december previously johnson december dollar million share datum report disposition report disposition net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earning discontinue operation net earning common share dilute net earning continue operation net earning discontinue operation net earning common share quarter fourth quarter adjust adjust report report mead mead previously johnson december previously johnson december dollar million share datum report disposition report disposition net sale gross margin net earning continue operation net earning continue operation attributable noncontrolle interest net earning continue operation attributable bms net earning discontinue operation attributable bms net earning attributable bms eps attributable bms basic net earning continue operation net earning discontinue operation net earning common share dilute net earning continue operation net earning discontinue operation net earning common share table content follow specify expenseincome item recognize affected comparability result dollar million quarter second quarter quarter fourth quarter year productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale product line business asset litigation charge accelerate depreciation bms foundation funding initiative loss sale investment upfront license milestone payment medarex acquisition debt buyback swap termination product liability income taxis item decrease net earning continue operation dollar million quarter second quarter quarter fourth quarter year productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment shutdown cost pension settlementscurtailment process standardization implementation cost gain sale leaseback property termination lease contract gain sale product line business litigation settlement insurance recovery product liability upfront licensing milestone payment acquire inprocess research development asset impairment ar impairment lossgain sale debt buyback swap termination gain sale imclone share income taxis item decreaseincrease net earning continue operation table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income retain earning cash flow year period end december audits include financial statement schedule list index item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position bristolmyer squibb company subsidiary december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion financial statement schedule consider relation basic consolidated financial statement take present fairly material respect information set forth discuss note consolidated financial statement company adopt accounting standard relate business combination effective business combination enter january audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp parsippany new jersey february table content item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting quarter company upgrade integrate sap general ledger new consolidation financial reporting warehouse fourth quarter company implement new process new sap system human resource relate activity include payroll certain international market simultaneously company outsource certain human resource transaction processing activity ibm transfer previously outsource payroll transaction processing activity accenture ibm item information table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule include explanatory paragraph company adoption account standard relate business combination effective business combination enter january deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item table content item